John H. Stewart, IV, M.D., M.B.A., FACS

Morehouse School of Medicine

Atlanta, Georgia

**Primary academic appointment:** Department of Surgery

**Academic Rank and Date of Appointment:** Professor of Surgery

**Academic Title:** Chair, Department of Surgery and Associate Dean for Oncology Programs

**Medical licensure:** North Carolina License #2004-01335

Georgia License # 97701

# Specialty certification(s) and dates (Month/Day/Year):

American Board of Surgery Certificate # 062132 Original Certification October 12, 2005

Recertification on December 14, 2016

Recertification on September 21, 2018

Recertification on November 2, 2020

Recertification on December 1, 2022

**Date of birth:** November 19, 1969 **Place:** Shreveport, LA, USA **Citizen of:** United States

|  |  |  |  |
| --- | --- | --- | --- |
| **Education: High School** | **Program and Institution** Loyola College Preparatory Shreveport, LA | **Date (Year)**  1987 | **Degree**  Diploma |
| **College** | Bachelor of Science- Zoology  Louisiana Tech University (Honors) Ruston, LA | 1991 | B.S.  (Zoology) |
| **Medical School** | Medical Doctor  Howard University College of Medicine Washington, DC | 1995 | M.D. |
| **Leadership** | Leadership Development for Physicians Harvard School of Public Health Boston, MA | 2011 | N/A |
| **Business School** | Master’s in Business Administration Wake Forest University  Winston-Salem, NC | 2014 | M.B.A. |

(Use continuation pages when necessary. If you wish, you may input this form in your computer for completion.)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Health Policy** | U.S. Health Policy Reform Harvard School of Public Health Boston, MA | | 2015 |  | N/A |  |
| **Management** |  | | 2020 |  | N/A |
|  | Massachusetts Institute of Technology | |  |  |  |
|  | Boston, MA | |  |  |  |
| **AI Technology** | Artificial Intelligence: Implications for Business Strategy  Machine Learning | | 2020 |  | N/A |
|  | Artificial Intelligence in Health Care | |  |  |  |  |
|  | Massachusetts Institute of Technology | |  |  |  |  |
|  | Boston, MA | |  |  |  |  |
| **Scholarly societies:** Alpha Omega Alpha | |  | | |  | |
| **Professional training and academic career:** | |  | | |  | |
| **Institution** | | **Position/Title** | | | **Dates** | |
| Temple University School of Medicine | | Resident in General Surgery | | | 1995-1998 | |
| Philadelphia, PA | |  | | |  | |
| National Institutes of Health | | Tumor Immunotherapy Fellow | | | 1998-1999 | |
| Bethesda, MD | |  | | |  | |
| National Institutes of Health | | Surgical Oncology Fellow | | | 1999-2002 | |
| Bethesda, MD | |  | | |  | |
| Vanderbilt University | | Resident in General Surgery | | | 2002-2004 | |
| Nashville, TN | |  | | |  | |
| Wake Forest School of Medicine | | Instructor in Surgery | | | 2004-2005 | |
| Winston-Salem, NC | |  | | |  | |
| Wake Forest School of Medicine | | Researcher, Maya Angelou Center | | | 2004-2015 | |
| Winston-Salem, NC | |  | | |  | |
| Wake Forest School of Medicine | | Assistant Professor of Surgery | | | 2005-2010 | |
| Winston-Salem, NC | |  | | |  | |
| Wake Forest School of Medicine | | Faculty, Nanotechnology Group | | | 2005-2015 | |

|  |  |  |
| --- | --- | --- |
| Winston-Salem, NC  Wake Forest School of Medicine Winston-Salem, NC | Associate Professor of Surgery | 2010-2015 |
| Wake Forest School of Medicine Winston-Salem, NC | General Surgery Residency Program Director | 2010-2015 |
| Wake Forest Comprehensive Cancer Center Winston-Salem, NC | Associate Director of Health Equity | 2012-2015 |
| Wake Forest School of Medicine Winston-Salem, NC | Vice Chair, Department of Surgery | 2012-2015 |
| Wake Forest School of Medicine Winston-Salem, NC | Associate Dean for Clinical Research | 2013-2015 |
| Wake Forest School of Medicine Winston-Salem, NC | Associate Professor Molecular Medicine | 2014-2015 |
| Duke University School of Medicine Durham, NC | Associate Professor of Surgery Chief of Surgery, Durham VAMC | 2015-2018 |
| University of Illinois, School of Medicine | Professor of Surgery  Physician Executive, Oncology Services | 2018- 2021 |

Deputy Director, University of Illinois Cancer Center Cancer Center Associate Director for Clinical Sciences Chair, Committee on Cancer

Louisiana State University, New Orleans Professor of Surgery 2021-2023

Director, LSU-LCMC Cancer Center Physician Executive, Oncology Services

Morehouse School of Medicine Professor of Surgery 2023-present

Chair of Surgery

Associate Dean of Oncology Programs

**Areas of research interests:** Developmental Oncoimmunotherapeutics Surgical Oncology

Clinical Trials

Artificial Intelligence in Healthcare

Delivery of Cancer Therapy to Underserved Populations

Healthcare Finance Healthcare Policy Healthcare Strategy Healthcare Operations

**Professional Board of Directors** SciWorks Science Museum Forsyth Country Day School American Board of Surgery Halsted Society

Scientific Advisory Board, AmunBio

Scientific Advisory Board, Equis Sciences

# Publications:

1. **Refereed journals:**
   1. **Stewart JH**, Rosenberg SA. Long Term Survival of Anti-Tumor Lymphocytes Generated by Vaccination with a Peptide Vaccine. *The Journal of Immunotherapy*, 22(4):401-404, July-August 2000.
   2. Weiser TS, Guo ZS, Parkhurst ML, Tong-On P, Marincola FM, Fischette MR, Yu X, Chen GA, Hong JA, **Stewart JH**, Nguyen DM, Rosenberg SA, Schrump DS. Sequential 5-Aza-2'- deoxycytidine (DAC)/Depsipeptide FR901228 (DP) Treatment Induces Apoptosis Preferentially in Cancer Cells and Facilitates their Recognition by Cytolytic T Lymphocytes Specific for NY-ESO-1. *Journal of Immunotherapy*, 24(2):151-161, March-April 2001.
   3. Nguyen DM, Lorang D, Chen A, **Stewart JH**, Tabibi E, Schrump DS. Enhancement of Paclitaxel- Mediated Cytotoxicity in Lung Cancer Cells by 17-AllylaminoGeldanamycin (17-AAG): In Vitro and In Vivo Analysis. *Annals of Thoracic Surgery*, 72(2):371-379, August 2001.
   4. **Stewart JH IV**, Nguyen DM, Chen A, Schrump DS. Induction of Apoptosis in Malignant Pleural Mesothelioma (MPM) Cells by Activation of the Fas (APO-1/CD95) Death Signal Pathway. *Journal of Thoracic and Cardiovascular Surgery*, 123(2):295-302, February 2002.
   5. Finkelstein SE, Summers RM., Nguyen D, **Stewart JH IV**, Schrump DS. Virtual Bronchoscopy (VB) in the Evaluation of Thoracic Malignancies. *Journal of Thoracic and Cardiovascular Surgery*, 123(5):967-972, May 2002.
   6. Nguyen DM, Schrump WD, Tsai WS, Chen AG, **Stewart JH**, Steiner F, Schrump DS. Enhancement of Depsipeptide-Mediated Apoptosis of Lung or Esophageal Cancer Cells By Flavopiridol: Activation of the Mitochondria-Dependent Death Signaling Pathway. *Journal of Thoracic and Cardiovascular Surgery*, 125(5):1132-1142, May 2003.
   7. Tafra L, Cheng Z, Uddo J, Lobrano MB, Stein W, Berg W, Levine E, Weinberg I, Narayanan D, Ross E, Beylin D, Yarnall S, Keen R, Sawyer K, Van Geffen J, Freimanis R, Staab E, Adler L, Lovelace J, Shen P, **Stewart J**, Dolinksky S. Pilot Clinical Trial of FDG Positron Emission Mamography (PEM) in the Surgical Management of Breast Cancer. *American Journal of Surgery*, 190(4):628-632, October 2005.
   8. Schrager JJ, Vnencal-Jones CL, Graber SE, Neff AT, Chari RS, Wright KJ, Pinson CW, **Stewart JH**, Gorden DL. Use of Short Tandem Repeats for DNA Fingerprinting to rapidly Diagnose Graft- versus-Host Disease in Solid Organ Transplant Patients. *Transplantation*, 81(1):21-25, Jan 2006.
   9. **Stewart JH**, Shen P, Russell GB, Bradley RF, Hundley JC, Loggie BW, Geisinger KR, Levine EA. Appendiceal Neoplasms with Peritoneal Dissemination: Outcomes after Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy. *Annals of Surgical Oncology*, 13(5):624-634, May 2006*.*
   10. Bradley RF, **Stewart JH**, Russell G, Levine E, Geisinger K. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 Patients Uniformly Treated at a Single Institution, with Literature Review. *American Journal of Surgical Pathology*, 30(5):551-559, May 2006.
   11. Mondi MM, Cuenca RE, Ollila DW, **Stewart JH 4th**, Levine EA. Sentinel Lymph Node Biopsy During Pregnancy: Initial Clinical Experience. *Annals of Surgical Oncology*, 14(1):218-221, Jan 2007.
   12. McQuellon RP, Danhauer SC, Russell GB, Shen P, Fenstermaker J, **Stewart JH**, Levine EA. Monitoring Health Outcomes Following Cytoreductive Surgery Plus Intraperitoneal Hyperthermic

Chemotherapy for Peritoneal Carcinomatosis. *Annals of Surgical Oncology*, 14(3):1105-13, Mar 2007.

* 1. Soo V, Shen P, Pichardo R, Azzazy H, **Stewart JH**, Geisinger KR, Levine EA. Intraoperative Evaluation of Sentinel Lymph Nodes for Metastatic Melanoma by imprint Cytology. *Annals of Surgical Oncology*, 14(5):1612-7, May 2007.
  2. Levine EA, **Stewart JH**, Russell GB, Geisinger KR, Loggie BL, Shen P. Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Surface Malignancy: Experience with 501 procedures. *Journal of the American College of Surgeons*, 204(5):943-953, May 2007.
  3. **Stewart JH 4th**, Tran TL, Levi N, Tsai WS, Schrump DS, Nguyen DM. The Essential Role of the mitochondria and reactive oxygen species in Cisplatin-mediated enhancement of fas ligand-induced apoptosis in malignant pleural mesothelioma. *Journal of Surgical Research*, 141(1):120-31, Jul 2007.
  4. Kilpatrick LA., Shen P, **Stewart JH**, Levine EA. Utility of Sentinel Lymph Node Biopsy for Melanoma of the Head and Neck. *The American Surgeon*, 73(8):754-759, Aug 2007.
  5. **Stewart JH**, Bertoni AG, Staten JL, Levine EA, Gross CP. Participation in Surgical Oncology Clinical Trials: Gender-, Race/Ethnicity-, and Age-based Disparities. *Annals of Surgical Oncology*, 14(12):3328-3334, Dec 2007.
  6. McQuellon RP, Russell GB, Shen P, **Stewart JH 4th**, Saunders W, Levine EA. Survival and health outcomes after cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of appendiceal origin. *Annals of Surgical Oncology*, 15(1):125-33, Jan 2008.
  7. Jackson LC, Camacho F, Anderson RT, **Stewart JH**. Patterns of Care Analysis Among Women with DCIS in North Carolina. *American Journal of Surgery*, 195(2):164-169, Feb 2008.
  8. **Stewart JH,** Shen P, Russell G, Fenstermaker J, McWilliams, Coldrun FM, Levine KE, Jones BT, Levine EA. A Phase I Trial of Oxaliplatin for Intraperitoneal Hyperthermic Chemoperfusion for the Treatment of Peritoneal Surface Dissemination From Colorectal and Appendiceal Cancer. *Annals of Surgical Oncology*, 15(8):2137-45, Aug 2008.
  9. Shen P, Thai K, **Stewart JH**, Howerton, Loggie, Russell G, Levine EA. Peritoneal Surface disease from colorectal cancer: comparison to the hepatic metastases surgical paradigm in optimally resected patients. *Annals of Surgical Oncology*, 15(12):3422-32, Dec 2008. Epub 2008 Sept 11.
  10. Wong SL, Young YD, Geisinger KR, Shen P, **Stewart JH**, Levine EA, Sangueza O, Pichardo- Geisinger R. Intraoperative Imprint Cytology for Evaluation of Sentinel Lymph Nodes from Merkel Cell Carcinoma. *American Surgeon*, 75(7):615-619, July 2009.
  11. Wood B, David LR, DeFranzo AJ, **Stewart JH**, Shen P, Geisinger KR, Marks, MW, Levine EA. Impact of Sentinel Lymph Node Biopsy on Immediate Breast Reconstruction Following Mastectomy. *American Surgeon*, 75(7):551-557, July 2009*.*
  12. Godat LN, Horton JK, Shen P, **Stewart JH**, Wentworth S, Levine EA. Recurrence After Mastectomy for Ductal Carcinoma in Situ. *American Surgeon*, 75(7):592-597, July 2009.
  13. Levi-Polyachenko NH, Merkel EJ, Jones BT, Carroll DL, **Stewart JH 4th.** Rapid Photothermal Intracellular Drug Delivery Using Multi-Walled Carbon Nanotubes. *Molecular Pharmaceutics*, 6(4):1092-1099, Aug 2009.
  14. Becher RD, Shen P, **Stewart JH**, Geisinger KR, McCarthy LP, Levine EA. Sentinel Lymph Node Mapping for Gastric Adenocarcinoma. *American Surgeon*, 75(8):710-4, Aug 2009.
  15. Varban O, Levine EA, **Stewart JH**, McCoy TP, Shen P. Outcomes associated with cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in colorectal cancer patients with peritoneal surface disease and hepatic metastases. *Cancer*, 115(15):3427-36, Aug 2009.
  16. Blackham AU, Shen P, **Stewart JH**, Russell GB, Levine EA. Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy for Malignant Peritoneal Mesothelioma: Mitomycin Versus Cisplatin. *Ann Surg Oncol*, 17(10):2720-7, Oct 2010.
  17. Esquivel J, Chua TC, Stojadinovic A, Melero JT, Levine EA, Gutman M, Howard R, Piso P, Nissan A, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Shen P, **Stewart JH**, Sugarbaker PH, Barone RM, Hoefer R, Morris DL, Sardi A, Sticca RP. Accuracy and Clinical Relevance of Computed Tomography Scan interpretation of Peritoneal Cancer Index in Colorectal Cancer Peritoneal Carcinomatosis: A Multi-Institutional Study. *Journal of Surgical Oncology*, 102(6):565- 70, Nov 2010.
  18. Rohani P, Scotti SD, Shen P ,**Stewart JH**, Russel GB, Cromer M, Levine EA. Imaging for Patients with Disseminated Cancer of the Appendix. *American Surgeon*, 76(12):1338-44, Dec 2010.
  19. Becher RD, Shen P, **Stewart JH**, Russell G, Bradley JF, Levine EA. Splenectomy Ameliorates Hematologic Toxicity of Hyperthermic Intraperitoneal Chemotherapy. *Journal of Gastrointestinal Oncology*, 2(2):70-76, Jun 2011. DOI: 10.3978/j.issn.2078-6891.2011.011.
  20. Winterich JA, Quandt SA, Grzywacz JG, Clark P, Dignan M, **Stewart JH**, Arcury TA. Men’s Knowledge and Beliefs about Colorectal Cancer and 3 Screenings: Education, Race, and Screening Status. *Am J Health Behav*, 35(5):525-534, Sept 2011. PMID: 22040614.
  21. Parson EN, Lentz S, Russell G, Shen P, Levine EA, **Stewart JH 4th**. Outcomes after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Dissemination from Ovarian Neoplasms. *Am J Surg*, 202(4):48:1-6, Oct 2011.
  22. Hill AR, McQuellon RP, Russell GB, Shen P, **Stewart JH**, Levine EA. Survival and quality of Life Following Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colonic Origin. *Ann Surg Oncol*, 18(13):3673-9, Dec 2011.
  23. **Stewart JH**, Ahmed M, Northrup SA, Willingham M, Lyles DS. Vesicular Stomatitis Virus as a Treatment for Colorectal Cancer. *Cancer Gene Ther*, 18(12):837-49, Dec 2011. doi: 10.1038/cgt.2011.49. Epub 2011 Sep 2.
  24. Howard-McNatt M, Geisinger KR, **Stewart JH**, Shen P, Levine EA. Is Intraoperative Imprint Cytology Evaluation Still Feasible for the Evaluation of Sentinel Lymph Nodes for Lobular Carcinoma of the Breast? *Ann Surg Oncol*, 19(3):929-34, Mar 2012. Epub 2011 Aug 31.
  25. Levine EA, Blazer DG, Kim MK, Shen P, **Stewart JH**, Guy C, Hsu DS. Gene Expression Profiling of Peritoneal Metastases from Appendiceal and Colon Cancer Demonstrates Unique Biologic Signatures and Predicts Patient Outcomes. *J Am Coll Surg*, 214(4):599-606, Apr 2012; discussion 606-7. Epub 2012 Feb 17.
  26. Votanopoulos KI, Ihemelandu C, Shen P, **Stewart JH**, Russell GB, Levine EA. Outcomes of Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Surface Malignancy. *J Am Coll Surg*, 215(3):412-7, May 2012.
  27. **Stewart JH 4th**, Shen P, Russell G, Fenstermaker J, McWilliams L, Coldrun FM, Levine KE, Jones BT, Levine EA. Erratum to: A Phase I Trial of Oxaliplatin for Intraperitoneal Hyperthermic Chemoperfusion for the Treatment of Peritoneal Surface Dissemination from Colorectal and Appendiceal Cancers. *Ann Surg Oncol*, 19(7):2421, Jul 2012.
  28. Duckworth KE, McQuellon RP, Russell G, Cashwell CS, Shen P, **Stewart JH**, Levine EA. Patient Reported Outcomes and Survivorship Following Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (CS+HIPEC). *Journal of Surgical Oncology*, 106(4):376-80, Sept 2012.
  29. Votanopoulos K, Ihemelandu C, Shen P, **Stewart JH**, Russell G, Levine EA. A Comparison of Hematologic Toxicity Profiles after Heated Intraperitoneal Chemotherapy with Oxaliplatin and Mitomycin-C. *Journal of Surgical Research*, 179(1):e133-9, Jan 2013.
  30. Blackham AU, Northrup SA, Willingham M, D'Agostino RB Jr, Lyles DS, **Stewart JH 4th.**

Variation in Susceptibility of Human Malignant Melanomas to Oncolytic Vesicular Stomatitis Virus.

*Surgery*, 153(3):333-343, Mar 2013.

* 1. Votanopoulos KI, Swett K, Blackham AU, Ihemelandu C, Shen P, **Stewart JH,** Levine EA. Cytoreductive Surgery (CS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Peritoneal Carcinomatosis (PC) from Rectal Cancer. *Ann Surg Oncol*, 20(4):1088-92, Apr 2013*.*

1. Howard-McNatt M, Lawrence J, Melin SA, Levine EA, Shen P, **Stewart JH 4th.** Race and Recurrence in Women who Undergo Neoadjuvant Chemotherapy for Breast Cancer. *Am J Surgery*, 205(4):397-401, Apr 2013.
2. Sun Y, Shen P, **Stewart JH**, Russell GB, Levine EA. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma. *Am Surg*, 79(6):644-8, Jun 2013.
3. Randle RW, Swett KR, Shen P, **Stewart JH**, Levine EA, Votanopoulos KI. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal sarcomatosis. *Am Surg*, 79(6):620-4, Jun 2013.
4. Votanopoulos KI, Newman NA, Russell G, Ihemelandu C, Shen P, **Stewart JH**, Levine EA. Outcomes of Cytoreductive Surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients older than 70 years; survival benefit at considerable morbidity and mortality. *Ann Surg Oncol*, 20(11):3497-503, Oct 2013.
5. Ihemelandu CU, McQuellon R, Shen P, **Stewart JH**, Votanopoulos K, Levine EA. Predicting postoperative morbidity following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CS+HIPEC) with preoperative FACT-C (Functional Assessment of Cancer Therapy) and patient-rated performance status. *Ann Surg Oncol*, 20(11):3519-2, Oct 2013.
6. Votanopoulos KI, Swords DS, Swett KR, Randle RW, Shen P, **Stewart JH**, Levine EA. Obesity and peritoneal surface disease: outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colon primary tumors. *Ann Surg Oncol*, 20(12):3899-904, Nov 2013.
7. Randle RW, Northrup SA, Sirintrapun SJ, Lyles DS, **Stewart JH 4th**. Oncolytic vesicular stomatitis virus as a treatment for neuroendocrine tumors. *Surgery*, 154(6):1323-29, Dec 2013; discussion 1329-3.
8. Blackham AU, Swett K, Eng C, Sirintrapun J, Bergman S, Geisinger KR, Votanopoulos K, **Stewart JH**, Shen P, Levine EA. Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *J Surg Oncol*. 2013 Dec 28. doi: 10.1002/jso.23547.
9. Votanopoulos KI, Randle RW, Craven B, Swett KR, Levine EA, Shen P, **Stewart JH**, Mirzazadeh

M. Significance of Urinary Tract Involvement in Patients Treated with Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). *Ann Surg Oncol*, 21(3):868-74, Mar 2014.

1. Levine EA, **Stewart JH 4th,** Shen P, Russell GB, Loggie BL, Votanopoulos KI. Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. *J Am Coll Surg*, 218(4):573-85, Apr 2014.
2. Blackham AU, Northrup SA, Willingham M, Sirintrapun J, Russell GB, Lyles DS, **Stewart JH 4th**. Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma. *J Surg Res*, 187(2):412-26, Apr 2014. pii: S0022-4804(13)00977-3. doi: 10.1016/j.jss.2013.10.032.
3. Randle RW, Swett KR, Swords DS, Shen P, **Stewart JH**, Levine EA, Votanopoulos KI. Efficacy of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in the Management of Malignant Ascites. *Ann Surg Oncol*, 21(5):1474-9 May 2014.
4. Blackham AU, Swett K, Eng C, Sirintrapun J, Bergman S, Geisinger KR, Votanopoulos K, **Stewart JH,** Shen P, Levine EA. Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *J Surg Oncol*, 109(7):740-5, Jun 2014.
5. Randle RW, Levine EA, Clark CJ, **Stewart JH,** Shen P, Votanopoulos KI. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for gallbladder cancer: a retrospective review. *Am Surg*, 80(7):710-3, Jul 2014.
6. Blackham AU, Russell GB, **Stewart JH 4th**, Votanopoulos K, Levine EA, Shen P. Metastatic colorectal cancer: survival comparison of hepatic resection versus cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Ann Surg Oncol*, 21(8):2667-74, Aug 2014.
7. Sirintrapun SJ, Blackham AU, Russell G, Votanopoulos K, **Stewart JH,** Shen P, Levine EA, Geisinger KR, Bergman S. Significance of signet ring cells in high-grade mucinous adenocarcinoma of the peritoneum from appendiceal origin. *Hum Pathol*, 45(8):1597-604, Aug 2014.
8. Ahmed S, Lawrence J, **Stewart JH,** Melin S, Levine EA, Howard-McNatt M. Does age predict outcome in patients with inflammatory breast cancer? *Am Surg*, 80(8):221-4, Aug 2014.
9. Bryan ML, Fitzgerald NC, Levine EA, Shen P, **Stewart JH,** Votanopoulos KI. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in sarcomatosis from gastrointestinal stromal tumor. *Am Surg*, 80(9):890-5, Sep 2014.
10. Ahmed S, **Stewart JH,** Shen P, Votanopoulos KI, Levine EA. Outcomes with cytoreductive surgery and HIPEC for peritoneal metastasis. *J Surg Oncol*, 110(5):575-84, Oct 2014.
11. Ahmed S, Levine EA, Randle RW, Swett KR, Shen P, **Stewart JH**, Votanopoulos KI. Significance of diaphragmatic resections and thoracic chemoperfusion on outcomes of peritoneal surface disease treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). *Ann Surg Oncol*, 21(13):4226-31, Dec 2014. doi: 10.1245/s10434-014-3891-3. Epub 2014 Jul 18. PubMed PMID: 25034815; PubMed Central PMCID: PMC4221464.
12. Neal MT, Chang MD, Lucas JT Jr, Loganathan A, Dillingham C, Pan E, **Stewart JH 4th,** Bourland JD, Shaw EG, Tatter SB, Ellis TL. Predictors of Survival, Neurologic Death, Local Failure and Distant Failure after Gamma Knife Radiosurgery for Melanoma Brain Metastases. *World Neurosurg*, 82(6):1250-5, Dec 2014.
13. Votanopoulos KI, Russell G, Randle RW, Shen P, **Stewart JH**, Levine EA. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases. *Ann Surg Oncol*, 22(4):1274-9, Apr 2015. doi: 10.1245/s10434-014-4147-y. Epub 2014 Oct 16. PubMed PMID: 25319583; PubMed Central PMCID: PMC4346452.
14. Randle RW, Doud AN, Levine EA, Clark CJ, Swett KR, Shen P, **Stewart JH**, Votanopoulos KI. Peritoneal surface disease with synchronous hepatic involvement treated with Cytoreductive Surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). *Ann Surg Oncol*, 22(5):1634-8, May 2015. doi: 10.1245/s10434-014-3987-9. Epub 2014 Aug 14. PubMed PMID: 25120252;

PubMed Central PMCID: PMC4329114.

1. Doud AN, Randle RW, Clark CJ, Levine EA, Swett KR, Shen P, **Stewart JH,** Votanopoulos KI. Impact of Distal Pancreatectomy on Outcomes of Peritoneal Surface Disease Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. *Ann Surg Oncol*, 22(5):1645-50, May 2015.
2. Randle RW, Ahmed S, Levine EA, Fino NF, Swett KR, **Stewart JH**, Shen P,Votanopoulos KI. Significance of diabetes on morbidity and mortality following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. *J Surg Oncol.* 2015 May;111(6):740-5. doi: 10.1002/jso.23865. Epub 2014 Dec 29. PubMed PMID: 25556634; PubMed Central PMCID: PMC4406797.
3. Randle RW, Griffith KF, Fino NF, Swett KR, **Stewart JH 4th**, Shen P, Levine EA, Votanopoulos KI. Appendiceal goblet cell carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *J Surg Res*, 196(2):229-34, Jun 2015. doi: 10.1016/j.jss.2015.03.051. Epub 2015 Mar 24. PubMed PMID: 25881787.
4. Doud AN, Levine EA, Fino NF, **Stewart JH**, Shen P, Votanopoulos KI. Stoma Creation and Reversal After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. *Ann Surg Oncol.* 2016 Feb;23(2):503-10. doi:10.1245/s10434-015-4674-1. Epub 2015 Jun 16. PubMed PMID: 26077915; PubMed Central PMCID: PMC4681681.
5. Mogal HD, Levine EA, Russell G, Shen P, **Stewart JH**, Votanopoulos KI. Conditional Survival After Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Low- and High-Grade Appendiceal Primaries. *Ann Surg Oncol.* 2015 Aug 20. [Epub ahead of print] PubMed PMID: 26289808.
6. Cummins KA, Russell GB, Votanopoulos KI, Shen P, **Stewart JH,** Levine EA. Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). *J Gastrointest Oncol.* 2016 Feb;7(1):3-9. doi: 10.3978/j.issn.2078-6891.2015.101. PubMed PMID: 26941979.
7. Valente K, Blackham AU, Levine E, Russell G, Votanopoulos KI, **Stewart JH,** Shen P, Geisinger KR, Sirintrapun SJ. A Histomorphologic Grading System That Predicts Overall Survival in Diffuse Malignant Peritoneal Mesothelioma With Epithelioid Subtype. *Am J Surg Pathol.* 2016 Sep;40(9):1243-8. doi:10.1097/PAS.0000000000000696. PubMed PMID: 27438989.
8. Clark JI, Wong MK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, **Stewart JH**, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Rudraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Amin A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, Agarwal N, Taback B, Treisman JS, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S. Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM(SM). *Clin Genitourin Cancer*. 2017 Feb;15(1):31-41.e4. doi: 10.1016/j.clgc.2016.10.008. Epub 2016 Oct 29. PMID:27916626.
9. Votanopoulos KI, Shen P, **Stewart JH,** Levine EA; Wake Forest HIPEC Group. Outcomes of Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients Older than 70 Years; Survival Benefit at Considerable Morbidity and Mortality: A Reply. *Ann Surg Oncol.* 2017 Dec;24(Suppl 3):602. doi: 10.1245/s10434-017-6220-9. Epub 2017 Nov 13. PubMed

PMID: 29134373.

1. Levine EA, Votanopoulos KI, Shen P, Russell G, Fenstermaker J, Mansfield P, Bartlett D, **Stewart JH.** A Multicenter Randomized Trial to Evaluate Hematologic Toxicities after Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin or Mitomycin in Patients with Appendiceal Tumors. *J Am Coll Surg*. 2018 Jan 10. pii: S1072-7515(17)32190-7. doi: 10.1016/j.jamcollsurg.2017.12.027. [Epub ahead of print] PubMed PMID: 29331663.
2. Clark CJ, Hildreth A, Migaly J, Sieren L, Carter J, **Stewart JH 4th.** Supervisor, Colleague, or Assistant: General Surgery Resident Perceptions of Advanced Practitioners. *Am Surg.* 2018 Feb 1;84(2):294-299. PubMed PMID: 29580361.
3. Day G, Bryan ML, Northrup SA, Lyles DS, Westcott MM, **Stewart JH 4th.** Immune Effects of M51R Vesicular Stomatitis Virus Treatment of Carcinomatosis from Colon Cancer. *Journal of Surgical Research.* 2019 Aug 12;245:127-135. doi: 10.1016/j.jss.2019.07.032. [Epub ahead of print PMID: 31415934. Masoud SJ, Hu JB, Beasley GM, **Stewart JH**, Mosca PJ. Efficacy of Talimogene Laherparepvec (TVEC) in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size. *Annals of Surgical Oncology.* 2019 Aug 14. doi: 10.1245/s10434-019-07691-3. [Epub ahead of print] PMID: 31414290.
4. Moaven O, Votanopoulos KI, Shen P, Mansfield P, Bartlett DL, Russell G, McQuellon R, **Stewart JH,** Levine EA. Health-Related Quality of Life After Cytoreductive Surgery/HIPEC for Mucinous Appendiceal Cancer: Results of a Multicenter Randomized Trial Comparing Oxaliplatin and Mitomycin. Ann Surg Oncol. 2019 Nov 12. doi: 10.1245/s10434-019-08064-6. [Epub ahead of print] PubMed PMID:31720933.
5. Fayanju OM, Ren Y, Thomas S, Greenup RA, Hyslop T, Hwang ES, **Stewart JH.** A Case-control Study Examining Disparities in Clinical Trial Participation among Breast Surgical Oncology Patients. *JNCI Cancer Spectrum*. 2019 Dec 16. doi: 10.1093/jncics/pkz103.
6. Tossas KY, Watson KS, Colditz GA, Thomas CR, **Stewart JH,** Winn RA. Advocating for a

"Community to bench model" in the 21st century. EBioMedicine. 2020 Mar;53:102688. doi: 10.1016/j.ebiom.2020.102688. PMID:32114395; PMCID: PMC7047196.

1. **Stewart JH 4th,** Blazer DG 3rd, Calderon MJG, Carter TM, Eckhoff A, Al Efishat MA, Fernando DG, Foster JM, Hayes-Jordan A, Johnston FM, Lautz TB, Levine EA, Maduekwe UN, Mangieri CW, Moaven O, Mogal H, Shen P, Votanopoulos KI. The Evolving Management of Peritoneal Surface Malignancies. Current Problems in Surgery. 2021Apr;58(4):100860. doi: 10.1016/j.cpsurg.2020. 100860.
2. **Stewart JH 4th**, Butler PD, Tseng JF, Kennard AC, Mellinger JD, Buyske J. Acknowledgment, Reflection, and Action: The American Board of Surgery Leans into Antiracism. Annals of Surgery. 2021 Apr 1;273(4):619-622. doi:10.1097/SLA.0000000000004684. PMID: 33351484.
3. Johnston FM, Yeo HL, Clark C, **Stewart JH 4th**. Bias Issues in Colorectal Cancer Management: A Review. Ann Surg Oncol. 2021 Jun 17. doi:10.1245/s10434-021-10232-6. Epub ahead of print. PMID: 34142287.
4. McIntyre C, Yeo HL, Clark C, **Stewart JH 4th**, Johnston FM. ASO Author Reflections: Colorectal Cancer, Bias, and the Surgeon: What is Next? Ann Surg Oncol. 2021 Jun 21. doi: 10.1245/s10434- 021-10264-y. Epub ahead of print. PMID: 34152522.
5. Asare EA, Swami U, **Stewart JH 4th.** Landmark Series on Disparities in Surgical Oncology: Melanoma. Ann Surg Oncol. 2021 Nov;28(12):6986-6993. doi: 10.1245/s10434-021-10273-x. Epub 2021 Jun 30. PMID: 34191178.
6. Stewart BA, **Stewart JH 4th.** Disparities in Clinical Trial Participation:Multilevel Opportunities for Improvement. Surg Oncol Clin N Am. 2022.Jan;31(1):55-64. doi: 10.1016/j.soc.2021.07.007. Epub 2021 Oct 19. PMID:34776064.
7. Abbas A, Diaz A, Obeng-Gyasi S, Cloyd JM, Ejaz A, **Stewart JH 4th,** Pawlik TM. Disparity in Clinical Trial Participation Among Patients with Gastrointestinal Cancer. J Am Coll Surg. 2022 Apr 1;234(4):589-598. doi:10.1097/XCS.0000000000000129. PMID: 35290279.

# Published scientific reviews (all peer-reviewed):

* 1. **Stewart JH**. Lung Carcinoma in African Americans: A Review of The Current Literature. *Cancer*, 91(12):2476-2482, Jun 2001.
  2. **Stewart JH**, Shen P, Levine EA. Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Surface Malignancy: Current Status and Future Directions. *Annals of Surgical Oncology*, 12(10): 765-777, Oct 2005.
  3. **Stewart JH 4th**, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy: an evolving paradigm for the treatment of peritoneal surface malignancies. *Expert Reviews in Anticancer Therapy*, 8(11):1809-18, Nov 2008.
  4. Shen P, **Stewart JH**, Levine EA. Metastases of colorectal cancer to the liver and peritoneum: comparison of surgical paradigms. *Expert Reviews in Anticancer Therapy*, 8(11):1797-808, Nov 2008.
  5. **Stewart JH 4th**, Shen P, Levine EA. Translational considerations for hyperthermic intraperitoneal chemotherapy. *Current Problems in Cancer*, 33(3):194-202, May-Jun 2009.
  6. Shen P, **Stewart JH 4th**, Levine EA. Cytoreductive Surgery and Intrapritoneal Hyperthermic Chemotherapy for Peritoneal Surface Malignancy: Non-Colorectal Indications. *Current Problems in Cancer*, 33(3): 168-93, May-Jun 2009.
  7. Shen P, **Stewart JH 4th**, Levine EA. The Role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer with peritoneal Surface Disease. *Current Problems in Cancer*, 33(3):154-67, May-Jun 2009.
  8. **Stewart JH 4th**, Levine EA, Shen P. The Current Role of Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Dissemination of Appendiceal Tumors. *Current Problems in Cancer*, 33(3):142-53, May-Jun 2009.
  9. Shen P, **Stewart JH 4th**, Levine EA. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy: Overview and Rationale. *Current Problems in Cancer*, 33(3):125-41, May-Jun 2009.
  10. Ihemelandu CU, Shen P, **Stewart JH**, Votanopoulos K, Levine EA. Management of Peritoneal Carcinomatosis from Colorectal Cancer. *Seminars in Oncology*, 38(4):468-75, Aug 2011.
  11. **Stewart JH**, Levine EA. Role of bacillus Calmette-Guérin in the treatment of advanced melanoma.

*Expert Rev Anticancer Ther*, 11(11):1671-6, Nov 2011.

* 1. Newman NA, Votanopoulos KI, **Stewart JH**, Shen P**,** Levine EA. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer. *Minerva Chir*, 67(4):309-318, Aug 2012.
  2. Votanopoulos KI, Shen P, **Stewart JH 4th**, Levine EA. Current status and future directions in appendiceal cancer with peritoneal dissemination. *Surg Oncol Clin N Am*, 21(4):599-609, Oct 2012. doi: 10.1016/j.soc.2012.07.012.
  3. Johnston FM, Yeo HL, Clark C, **Stewart JH 4th.** Bias Issues in Colorectal Cancer Management: A Review. *Ann Surg Oncol.* 2022 Apr;29(4):2166-2173. doi:10.1245/s10434-021-10232-6.
  4. Kumar V, **Stewart JH 4th.** Immunometabolic Reprogramming, Another Cancer Hallmark. *Frontiers in Immunology.* 2023 May 19;14:1125874. doi:10.3389/fimmu.2023.1125874. PMID: 37275901; PMCID: PMC10235624.
  5. Kumar V, Bauer C, **Stewart JH 4th.** Targeting cGAS/STING Signaling-mediated Myeloid Immune Cell Dysfunction in TIME. *Journal of Biomedical Sciences.* 2023 Jun 28;30(1):48.doi: 10.1186/s12929-023-00942-2. PMID: 37380989; PMCID: PMC10304357.
  6. Kumar V, Bauer C, **Stewart JH 4th.** TIME Is Ticking for Cervical Cancer. Biology (Basel). 2023 Jun 30;12(7):941. doi: 10.3390/biology12070941. PMID:37508372; PMCID: PMC10376148.
  7. Kumar V, **Stewart JH 4th.** Editorial: Immunology of cachexia. Front Immunol. 2023 Dec 5;14:1339263. doi: 10.3389/fimmu.2023.1339263. PMID: 38116001; PMCID:PMC10728869.
  8. Kumar V, **Stewart JH 4th.** Obesity, bone marrow adiposity, and leukemia: Time

to act. Obes Rev. 2023 Dec 13:e13674. doi: 10.1111/obr.13674. Epub ahead of print. PMID:38092420.

# Other:

1. **Selected abstracts**
2. **Stewart JH**, Spaulding JA. The Effect of Chronic Ethanol Ingestion on Femoral Bone Formation. Louisiana Academy of Sciences Annual Meeting, Shreveport, LA, February 1991.
3. **Stewart JH**, Hurt K, Leffall LD. Breast Cancer in Premenopausal African American Women. Student National Medical Association Scientific Session, Washington, DC, April 1995.
4. Nguyen DM, **Stewart JH**, Chen AG, Schrump DS. Strategies to Enhance Sensitivity to soluble Fas Ligand for Non-small Cell Lung Cancer and Esophageal Cancer. Programmed Cell Death Regulation: Basic Mechanisms and Therapeutic Opportunities, Lake Tahoe, NV, March 2000.
5. Yu X, Weiser TS, Guo ZS, Ohnmacht GA, Hong JA, **Stewart JH**, Chen GA, Nguyen DA and Schrump DS. 5 Aza 2´ Deoxycytidine and Depsipeptide FR901228 Mediate Growth Arrest and Apoptosis in Lung Cancer Cells Irrespective of Rb, p53, p16, p14/ARF, or p21 Expression. Selected for presentation, Keystone Symposia – Cell Cycle 2001, Taos, NM, January 9-14, 2001.
6. Schrump DS, Weiser TS, Yu X, Guo Z-S, Hong JA, Chen GA, Fischette MR, **Stewart JH IV**, Nguyen DM. 5 Aza 2´ Deoxycytidine (DAC) and Depsipeptide FR901228 (DP) Differentially Mediate Induction of Cancer Testis Antigen and Tumor Suppressor Gene Expression in Lung Cancer Cells. Selected for presentation, 5th Joint Conference of the American Association for Cancer Research and the Japanese Cancer Association, Maui, HI, February 12-16, 2001.
7. Schrump DS, Chen GA, Guo ZS, Yu X, **Stewart JH IV**, Fischette MR, Nguyen DM. Depsipeptide FR901228 (DP) Mediates Cell Cycle Arrest and Apoptosis in Malignant Pleural Mesothelioma (MPM) Cells Irrespective of SV40 T/t Antigen Status. Selected for presentation, Keystone Symposia – Cancer Intervention, Durango, CO, February 28-March 5, 2001.
8. Finkelstein SE, Schrump DS, Nguyen D, **Stewart JH**, Summers RM. Virtual Bronchoscopy (VB) in the Evaluation of Thoracic Malignancies. Accepted for oral presentation, 54th Annual Cancer Symposium of the Society of Surgical Oncology, Washington, DC, March 15-18, 2001.
9. **Stewart JH**, Nguyen DM, Chen A, Schrump DS. Induction of Apoptosis in Malignant Pleural Mesothelioma (MPM) Cells by Activation of the Fas (APO-1/CD95) Signal Pathway. Proceedings of the 92nd Annual Meeting, American Association for Cancer Research, New Orleans, LA, March 24-28, 2001.
10. Nguyen DM, Chen AG, Desai S, **Stewart JH IV**, Guo S, Hong J, Yu X, Wan H, Schrump DS. Downregulation of Malignant Phenotypes in Esophageal Cancer Cells Expressing High Levels of Epidermal Growth Factor Receptor (EGFR) by the EGFR-specific Tyrosine Kinase Inhibitor PD153035. Proceedings of the 92nd Annual Meeting, American Association for Cancer Research, New Orleans, LA, March 24-28, 2001.
11. Nguyen DM, Chen GA, **Stewart JH IV**, Guo S, Hong J, Yu X, Wan H, Schrump DS. Sensitization of Esophageal Cancer Cells Expressing High Levels of Epidermal Growth Factor Receptor (EGFR) to Chemotherapy (CT) or Irradiation (IR) by the EGFR-specific Tyrosine Kinase Inhibitor PD153035. Proceedings of the 92nd Annual Meeting, American Association for Cancer Research, New Orleans, LA, March 24-28, 2001.
12. Nguyen DM, Lorang D, Chen GA, **Stewart JH IV**, Guo Z-S, Yu X, Hong JA, Wan H, Schrump DS. Synergistic Tumoricidal Effect of the Paclitaxel and 17 Allylamino Geldanamycin (17AAG) Combination in Nonsmall Cell Lung Cancer: In Vitro and In Vivo Analysis. Proceedings of the 92nd Annual Meeting, American Association for Cancer Research, New Orleans, LA, March 24-28, 2001.
13. **Stewart JH IV**, Nguyen DM, Chen A, Schrump DS. Induction of Apoptosis in Malignant Pleural Mesothelioma (MPM) Cells by Activation of the Fas (APO-1/CD95) Death Signal Pathway. Oral presentation, 81st Annual Meeting, American Association for Thoracic Surgery, San Diego, CA, May 6-9, 2001.
14. **Stewart JH IV**. The Molecular Epidemiology of Lung Cancer in African Americans. Oral presentation, 8th Biennial Symposium on Minorities, the Medically Underserved and Cancer, Washington, DC, February 6-10, 2002.
15. Nguyen DM, **Stewart JH**, Chen GA, Mikulski S, Schrump DS. Enhancement of sFasL-mediated cytotoxicity in lung or esophageal cancer cells by cycloheximide, Onconase, or Cisplatin: Recruitment of the mitochondria-dependent death signaling pathway. AACR-sponsored special Conference in Cancer Research Apoptosis and Cancer: Basic Mechanisms and Therapeutic Opportunities in the Post-Genomic Era. Waikoloa, HI, February 13-17, 2002.
16. Nguyen DM, Schrump WD Schrump, **Stewart JH**, Chen GA, Steiner AG, Schrump DS. Flavopiridol Enhances Depsipeptide- Mediated Apoptosis in Lung and Esophageal Cancer Cells ViaActivation of Mitochondrial Death Signal Pathways. Proceedings of the 93rd Annual Meeting, American Association for Cancer Research, San Francisco, CA, April 6-10, 2002.
17. **Stewart JH IV**, Chen GA, Schrump DS, Nguyen DM. The Central Role of Reactive Oxygen Species in Cisplatin Enhancement of Fas Ligand Mediated Apoptosis in Malignant Pleural Mesothelioma Cells. Proceedings of the 93rd Annual Meeting, American Association for Cancer Research, San Francisco, CA, April 6-10, 2002.
18. Nguyen DM, Schrump WD, **Stewart JH,** Steiner F, Chen A, Schrump DS. Enhancement of depsipeptide-mediated apoptosis of lung and esophageal cancer cells by the cyclin-dependent kinase inhibitor Flavopiridol. Proceedings of the 93rd Annual Meeting of the American Association for Cancer Research, San Francisco, CA, April 6-10, 2002.
19. Nguyen DM, Chen GA, **Stewart JH IV**, Guo S, Hong J, Yu X, Steiner FS, Schrump DS. The ErbB1 Antagonist PD153035 Inhibits DNA Repair and Potentiates Cisplatin or Radiation- Induced Apoptosis in Esophageal Cancer. Proceedings of the 93rd Annual Meeting, American Association for Cancer Research, San Francisco, CA, April 6-10, 2002.
20. **Stewart JH IV,** Shen P, Russell GB, Bradley RF, Hundley JC, Loggie KR, Geisinger KR, Levine EA. Appendiceal Neoplasm with Peritoneal Dissemination: Outcomes after Cytroreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy. Proceedings of the 58th Annual Cancer Symposium Meeting of The Society of Surgical Oncology, Atlanta, GA, March 3-6, 2005.
21. Levine EA, **Stewart JH**, Loggie BW, Geisinger KR, Russell GB, Shen P. Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Surface Malignancy: Experience with 501 Procedures. Oral presentation at the Southern Surgical Association Annual Meeting, Palm Beach, FL, December 2006.
22. Bradley RF, **Stewart JH**, Russell GB, Levine EA, Geisinger KR. Mucinous Carcinoma Peritonei as the Pathologic Counterpart of Pseudomyxoma Peritonei: 101 Patients with Primary Appendiceal Neoplasms, Uniformly Treated at One Institution. Lab Invest 2006; (Suppl 1): 103A. *Modern Pathology*, 19(Suppl 1):103A, 2006.
23. Soo V, Shen P, Pichardo R, Azzazy H, **Stewart JH**, Geisinger KR, Levine EA. Intraoperative Evaluation of Sentinel Lymph Nodes for Metastatic Melanoma by imprint Cytology. *Annals of Surgical Oncology*, 13(2 Suppl):13-14, 2006.
24. Kilpatrick LA, Shen P, **Stewart JH**, Levine EA. Utility of Sentinel Lymph Node Biopsy for Melanoma of the Head and Neck. Oral presentation at the Southeastern Surgical Congress, Savannah, GA, February 12, 2007.
25. Levine EA, **Stewart JH**, Shen P. Peritoneal Surface Malignancy: Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy. *The American Journal of Hematology/Oncology*, 6: 706-710, 2007.
26. **Stewart JH**, Bertoni AG, Staten JL, Levine EA, Gross CP. Participation in Surgical Oncology Clinical Trials: Gender-, Race/Ethnicity-, and Age-based Disparities. *Annals of Surgical Oncology*, 14(Suppl 2):29, 2007.
27. McQuellon RP, Russell GB, Shen P, **Stewart JH**, Saunders WW, Levine EA. Survival and Quality of Life (QOL) after Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy (IPHC) for Disseminated Peritoneal Cancer (PC) of Appendiceal Origin. *Annals of Surgical Oncology*, 14(Suppl 2):30-31, 2007.
28. Jackson LC, Camacho F, Anderson RT, **Stewart JH**. Patterns of Care Analysis Among Women with DCIS in North Carolina. *Annals of Surgical Oncology*, 14(Suppl 2):41-42, 2007.
29. **Stewart JH**, Tsai W, Schrump DS, Nguyen DM. The Essential Role of Reactive Oxygen Species in Cisplatin-Induced Sensitization of Malignant Pleural Mesothelioma Cells to Fas Ligand Mediated Apoptosis. *Journal of Surgical Research*, 137(2):167, 2007.
30. **Stewart JH**, Northrup S, Levi-Polyachenko N, Merkle E, Russell G, Jones B, Levine EA. Hyperthermia Enhances the Cytotoxic Effects of Oxaliplatin in Colorectal Cancer Cells. *Journal of Surgical Research*, 144(2):308, 2008.
31. Shen P, Thai K, **Stewart JH**, Howerton R, Loggie BW, Russell G, Levine EA. Isolated Metastases of Colorectal Cancer to the Liver or Peritoneum: Outcomes Associated with Optimal Surgical Treatment. *Annals of Surgical Oncology*, 15(Suppl 2):6, 2008.
32. **Stewart JH**, Shen P, Russell G, Fenstermaker J, McWilliams L, Coldrun FM, Levine KE, Jones BT, Levine EA. A Phase I Trial of Oxaliplatin for Intraperitoneal Hyperthermic Chemoperfusion for the Treatment of Peritoneal Surface Dissemination From Colorectal and Appendiceal Cancer. Oral presentation at the Society of Surgical Oncology meeting, Chicago, IL, March 2008.
33. Shen P, Thai K, **Stewart JH**, Howerton R, Loggie B, Russell G, Levine EA. Peritoneal Surface Disease from Colorectal Cancer: Comparison to the Hepatic Metastases Surgical Paradigm in Optimally Resected Patients. Oral presentation at the Society of Surgical Oncology meeting, Chicago, IL, March 2008.
34. Varban O, Levine EA, **Stewart JH**, McCoy TP, Shen P. Outcomes Associated with Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Colorectal Cancer Patients with Peritoneal Surface Disease and Hepatic Metastases. Oral presentation at the American HepatoPancreatoBiliary Association meeting, Ft. Lauderdale, FL, March 2008.
35. McQuellon R, Russell G, Campbell CR, Duckworth K, Beard R, Shen P, **Stewart JH**, Levine EA. Assessing Depressive Symptoms with the Center for Epidemiologic Studies Depression (CESD) Scale Prior to Cytoreductive Surgery + Intraperitoneal Hyperthermic Chemotherapy (CS + IPHC). American Psychosocial Oncology Society Poster Presentation, Charlotte, NC, February 2009.
36. Wood B, David LR, DeFranzo AJ, **Stewart JH**, Shen P, Geisinger KR, Marks MW, Levine EA. Impact of Sentinel Lymph Node Biopsy on Immediate Breast Reconstruction Following Mastectomy. Oral presentation at the Southeastern Surgical Congress, Atlanta, GA, February 2009.
37. Wong SL, Young YD, Geisinger KR, Shen P, **Stewart JH**, Levine EA, Sangueza O, Pichardo- Geisinger R. Intraoperative Imprint Cytology for Evaluation of Sentinel Lymph Nodes from Merkel Cell Carcinoma. Poster presentation at the Southeastern Surgical Congress, Atlanta, GA, February 2009.
38. Becher RD, Shen P, **Stewart JH**, Geisinger KR, McCarthy LP, Levine EA. Sentinel Lymph Node Mapping for Gastric Adenocarcinoma. Poster presentation at the Southeastern Surgical Congress, Atlanta, GA, February 2009.
39. Godat LN, Horton JK, Shen P, **Stewart JH**, Wentworth S, Levine EA. Recurrence After Mastectomy for Ductal Carcinoma in Situ. Oral presentation at the Southeastern Surgical Congress, Atlanta, GA, February 2009.
40. Blackham AU, Shen P, **Stewart JH**, Russell GB, Levine EA. Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy for Malignant Peritoneal Mesothelioma: Mitomycin vs. Cisplatin. Oral presentation at the Society of Surgical Oncology, Phoenix, AZ, March 2009.
41. **Stewart JH**, Northrup SA, Ahmed M, Lyles DS. Vesicular Stomatitis Virus as a Treatment for Colorectal Cancer. Presentation at NCI Translational Science Meeting, Vienna, VA, November 5-7, 2009.
42. Becher RD, Shen P, **Stewart JH**, Russell G, Bradley T, Levine EA. Splenectomy Ameliorates Hematologic Toxicity of Intraperitoneal Hyperthermic Chemotherapy. Poster Presentation at the Society of Surgical Oncology, St. Louis, MO, March 2010.
43. Votanopoulos KI, Shen P, **Stewart JH**, Russell G, Levine EA. A Comparison of Hematologic Toxicity Profiles after Heated Intraperitoneal Chemotherapy with Oxaliplatin and Mitomycin-CK.I. Poster Presentation at the Society of Surgical Oncology, St. Louis, MO, March 2010.
44. Parson N, Shen P, Russell GB, Lentz SS, Levine EA, **Stewart JH**. Outcomes after CytoreductiveSurgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Dissemination from Ovarian Neoplasms. Poster Presentation at the Society of Surgical Oncology, St. Louis, MO, March 2010.
45. Hill AR, McQuellon RP, Russell GB, Shen P, **Stewart JH**, Levine EA. Survival and Health-Related Quality of Life Following Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Disseminated Peritoneal Cancer of Colonic Origin. Oral Presentation at the Society of Surgical Oncology, St. Louis, MO, March 2010.
46. Kim MK, Blazer DG, **Stewart JH**, Guy C, Shen P, Levine EA, Hsu D. Use of Gene Expression Profiling to Determine Prognosis and Therapeutic Targets for Patients with Appendiceal Carcinoma. Poster Presentation at the 2011 Gastrointestinal Cancers Symposium, San Francisco, CA, January 20-22, 2011.
47. Duckworth KE, McQuellon RP, Russell G, Levine E, Shen P, **Stewart J**, Cromer M, Cashwell C. Quality of Life and Sleep quality of Long-Term Survivors of Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (CS+HIPEC). Poster Presentation at American Psychosocial Oncology Society 8th Annual Conference, Anaheim, CA, February 17-19, 2011.
48. Votanopoulos KI, Shen P, **Stewart JH**, Russell G, Levine EA. Efficacy of Repeat Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Peritoneal Survace Malignancy. Presentation at the Society of Surgical Oncology, San Antonio, TX, March 2011.
49. Aaron U Blackham M.D., Greg Russell M.S., **John H Stewart IV M.D.**, Konstantinos Votanopoulos M.D., Edward A Levine M.D., Perry Shen M.D. Long-term Survival after Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy Compared to Hepatic Resection for Metastatic Colorectal Cancer. ASCO 2012 Gastrointestinal Cancers Symposium, San Francisco, CA, January 19-21, 2012.
50. Konstantinos I Votanopoulos M.D., Katrina Swett M.S., Perry Shen M.D., **John H. Stewart M.D.,** Edward A. Levine M.D. Cytoreductive Surgery (CS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Peritoneal Carcinomatosis (PC) from Rectal Cancer. Oral Presentation at the Regional Cancer Therapies 7th International Symposium, Captiva, FL, February18-20, 2012.
51. Richard McQuellon Ph.D., Katharine Duckworth Ph.D., Greg Russell M.S., Perry Shen M.D., **John Stewart M.D**., Konstantinos Votanopoulos M.D., and Ed Levine, M.D. After Screening for Depression in a High Risk Medical Population: Then What? Poster presentation at the American Psychosocial Oncology Society 9th Annual Conference, Miami, FL, February 23-25, 2012.
52. Craven B, Shen P, Levine E, Votanopoulos KI, **Stewart J**, Mirzazadeh M. Urologic Reconstructive Procedures in Cytoreductive Surgery (CRS) and Intraperitoneal Hyperthermic Chemotherapy (HIPEC) for Peritoneal Surface Malignancy in 934 Consecutive Procedures. Poster presentation at SUFU 2012 Winter Meeting, New Orleans, LA, March 3, 2012.
53. Griffith K, Shen P, **Stewart J**, Votanopoulos KI, Russell G, Geisinger K, Levine E. Appendiceal Neuroendocrine Tumors with Peritoneal Surface Dissemination Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. The Society of Surgical Oncology 65th Annual Meeting, Orlando, FL, March 21-24, 2012.
54. Shen P, Gahagan J, **Stewart JH**, Votanopoulos KI, Swett K, Levine EA. Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis: Analysis of Postoperative Morbidity and Mortality from a High Volume Center. The Society of Surgical Oncology 65th Annual Meeting, Orlando, FL*,* March 21-24, 2012.
55. Votanopoulos KI, Newman NC, Shen P, **Stewart JH**, Russell G, Levine EA. Cytoreductive Surgery(CS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the elderly. The Society of Surgical Oncology 65th Annual Meeting, Orlando, FL*,* March 21-24, 2012.
56. Blackham A, Russell G, **Stewart J**, Votanopoulos KI, Levine E, Shen P. Patterns of Recurrence

after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy compared to Hepatic Resection in Optimally-Treated Patients with Metastatic Colorectal Cancer. American College of Surgeons Clinical Congress Chicago, IL, September 30-October 3, 2012.

1. Votanopoulos KI, Swett K, Swords D, Shen P, **Stewart JH**, Levine EA. Obesity and Peritoneal Surface Disease; Outcomes following Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Appendiceal and Colon Primaries. GI ASCO San Francisco, CA, January 26-28, 2013.
2. Randle RW, Swett KR, Swords DS, Shen P, **Stewart JH**, Levine EA, Votanopoulos KI. Efficacy of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in the Management of Malignant Ascites. 8th International Symposium on Regional Cancer Therapies in Indian Wells, CA, February 2013.
3. Votanopoulos KI, Swett K, Shen P, **Stewart JH**, Levine EA. Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Peritoneal Sarcomatosis. Southeastern Surgical Congress Annual Scientific Meeting, Jacksonville, FL, February 9-12, 2013.
4. Votanopoulos KI, Swett K, Swords D, Shen P, **Stewart JH**, Levine EA. Efficacy of Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the management of Malignant Ascites in patients with Peritoneal Surface Disease (PSD). 8th International Symposium on Regional Cancer Therapies, Indian Wells, CA, February 16-18, 2013.
5. Votanopoulos KI, Swett K, Swords D, Shen P, **Stewart JH**, Levine EA. Obesity and Peritoneal Surface Disease; Outcomes following Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Appendiceal and Colon Primaries. The Society of Surgical Oncology 66th Annual Meeting, National Harbor, MD*,* March 6-9, 2013.
6. Randle RW, Northrup SA, Sirintrapun SJ, Lyles DS, **Stewart JH 4th**. Oncolytic vesicular stomatitis virus as a treatment for neuroendocrine tumors. American Association for Endocrine Surgeons Meeting, April 2013.
7. Levine EA, **Stewart JH 4th,** Shen P, Russell GB, Loggie BL, Votanopoulos KI. Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. Presented at the 125th Annual Meeting of the Southern Surgical Association in Hot Springs, Virginia, December 2013.
8. Randle RW, Doud AN, Levine EA, Clark CJ, Swett KR, Shen P, **Stewart JH**, Votanopoulos KI. Peritoneal surface disease with synchronous hepatic involvement treated with Cytoreductive Surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Presented at the 9th Annual Academic Congress in San Diego, CA, February 2014.
9. Bryan ML, Levine EA, Shen P, **Stewart JH**, Votanopoulos KI. Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Sarcomatosis from Gastrointestinal Stromal Tumor (GIST). Poster. Southeastern Surgical Congress Annual Scientific Meeting, Savannah, GA, Feb 22-25, 2014.
10. Ahmed S, Levine EA, Swett KR, Randle RW, Shen P, **Stewart JH**, Votanopoulos KI. Significance of Diaphragmatic Resections and Thoracic Chemoperfusion on Outcomes of Peritoneal Surface Disease Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). Poster. The Society of Surgical Oncology 67th Annual Meeting, Phoenix, AZ, March 12-15, 2014.
11. Randle RW, Swett KR, **Stewart JH**, Shen P, Levine EA, Votanopoulos KI. Morbidity and Mortality following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in Patients with Diabetes. Poster. The Society of Surgical Oncology 67th Annual Meeting, Phoenix, AZ, March 12- 15, 2014.
12. Doud AN, Randle RW, Clark CJ, Levine EA, Swett KR, Shen P, **Stewart JH,** Votanopoulos KI. Impact of Distal Pancreatectomy on Outcomes of Peritoneal Surface Disease Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Presented at the 9th Annual Academic Congress in San Diego, CA, February 2014.
13. Randle RW, Ahmed S, Levine EA, Fino NF, Swett KR, **Stewart JH**, Shen P,Votanopoulos KI. Significance of diabetes on morbidity and mortality following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Presented at the Society of Surgical Oncology 67th Annual Cancer Symposium in Phoenix, AZ, March 2014.
14. Votanopoulos KI, Russell G, Randle RW, Shen P, **Stewart JH**, Levine EA. Peritoneal Surface Disease (PSD) from Appendiceal Cancer Treated with Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Overview of 481 cases. Presented at the Society of Surgical Oncology 67th Annual Meeting, Phoenix, AZ, March 2014.
15. Ahmed S, Levine EA, Randle RW, Swett KR, Shen P, **Stewart JH**, Votanopoulos KI. Significance of diaphragmatic resections and thoracic chemoperfusion on outcomes of peritoneal surface disease treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Presented at the Society of Surgical Oncology 67th Annual Cancer Symposium in Phoenix, AZ, March 2014.
16. Doud AN, Levine EA, Fino NF, **Stewart JH**, Shen P, Votanopoulos KI. Stoma Creation and Reversal After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Presented at the 10th Annual Academic Congress in Las Vegas, NV February 2015.
17. Mogal HD, Levine EA, Russell G, Shen P, **Stewart JH**, Votanopoulos KI. Conditional Survival After Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Low- and High-Grade Appendiceal Primaries. 10th International Symposium on Regional Cancer Therapies in Clearwater,FL, February 2015.
18. Levine EA, Votanopoulos KI, Shen P, Russell G, Fenstermaker J, Mansfield P, Bartlett D, **Stewart JH.** A Multicenter Randomized Trial to Evaluate Hematologic Toxicities after Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin or Mitomycin in Patients with Appendiceal Tumors. Presented at the 129th Annual Meeting of the Southern Surgical Association in Hot Springs, Virginia, December 2017.
19. Moaven O, Votanopoulos KI, Shen P, Mansfield P, Bartlett DL, Russell G, McQuellon R, **Stewart JH,** Levine EA. Health-Related Quality of Life After Cytoreductive Surgery/HIPEC for Mucinous Appendiceal Cancer: Results of a Multicenter Randomized Trial Comparing Oxaliplatin and Mitomycin. Presented at the Society of Surgical Oncology 72nd Annual Cancer Symposium in San Diego, CA, March 2019
20. **Stewart JH,**  Strickler J,  Mettu N,  MacLaughlan S,  Niedzwiecki D,  Levine E and  Blazer D. A Phase I Trial of Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO)  Journal for ImmunoTherapy of Cancer. Dec 2020, 8 (Suppl 3) A248-A249; DOI: 10.1136/jitc-2020-SITC2020.0409
21. Abbas A, Diaz A, Obeng-Gyasi S, Cloyd JM, Ejaz A, **Stewart JH 4th,** Pawlik TM. Disparity in Clinical Trial Participation Among Patients with Gastrointestinal Cancer. Presented at the 133rd Annual Meeting of the Southern Surgical Association in Hot Springs, Virginia, December 2021.

# Editorials, position, and background papers

1. **Stewart JH**. Transcriptional Targeting of Bone Morphogenetic Protein Receptors: Is it Ready for Prime Time? *J Surg Res*, 178(2):601-603, Dec 2012. 2011 Oct 11 [Epub ahead of print].
2. **Stewart JH 4th**, Kwayisi G, Cornwell EE 3rd. Asa G Yancey: a quiet giant in American surgery. *J Am Coll Surg*, 219(4):842-5, Oct 2014.
3. Callender GG, Kaplan BJ, White RL, Brenin DR, Chagpar AB, Dalal KM, Howard-McNatt M, Howe J, Kim J, Kurtzman SH, Mansour JC, Mittendorf EA, **Stewart JH 4th,** Temple LK, Stella P, Cummings C, Wong SL, Klimberg VS. Maintenance of certification: what everyone needs to know. *Ann Surg Oncol.* 2015 Apr;22(4):1051-4. doi: 10.1245/s10434-014-4306-1. Epub 2015 Feb 7. PubMed PMID:25663592.
4. **Stewart JH**. Conversation with the Cancer Letter. Oregon Draft Guidance is an Assault on the Treatment of Underrepresented Populations. *Cancer Letter.* September 26, 2018.
5. **Stewart JH,** Winn RA. Getting Beyond the Immunotherapy Divide: a Call to Action. *Cancer Letter.* May 3, 2019.
6. Tossas KY, Watson KS, Colditz GA, Thomas CR, **Stewart JH**, Winn RA. Advocating for a "Community to Bench Model" in the 21st century. *EBioMedicine*. 2020 Mar;53:102688. doi: 10.1016/j.ebiom.2020.102688. Epub 2020 Feb 27. PMID: 32114395; PMCID: PMC7047196.
7. **Stewart JH 4th,** Butler PD, Tseng JF, Kennard AC, Mellinger JD, Buyske J. Acknowledgement, Reflection, and Action: The American Board of Surgery Leans into Antiracism. Ann Surg. 2020 Dec 18; Published Ahead of Print. doi: 10.1097/SLA.0000000000004684. Epub ahead of print. PMID: 33351484.
8. McIntyre C, Yeo HL, Clark C, **Stewart JH 4th,** Johnston FM. ASO Author Reflections: Colorectal Cancer, Bias, and the Surgeon: What is Next? Ann Surg Oncol. 2022 Apr;29(4):2174-2175. doi: 10.1245/s10434-021-10264-y. Epub 2021 Jun 21. PMID: 34152522.
9. King K, Turner J, **Stewart JH.** Current state and need for more black surgeons in academic surgery. Am J Surg. 2022 Jul;224(1 Pt B):299-301. doi:10.1016/j.amjsurg.2022.02.040. Epub 2022 Feb 22. PMID: 35282871.
10. Asare EA, Andreae MH, **Stewart JH 4th.** Bridging the Disparity Gap in Surgical Oncology Access: Does Telehealth Hold a Key? Ann Surg Oncol. 2022 Nov;29(12):7235-7236. doi: 10.1245/s10434- 022-12262-0. Epub 2022 Jul 19. PMID:35854032; PMCID: PMC9296011.
11. Pugh CM, Kirton OC, Tuttle JEB, Maier RV, Hu YY, **Stewart JH 4th,** Freischlag JA, Sosa JA, Vickers SM, Hawn MT, Eberlein TJ, Farmer DL, Higgins RS, Pellegrini CA, Roman SA, Crandall ML, De Virgilio CM, Tsung A, Britt LD. Addressing theSurgical Workplace: An Opportunity to Create a Culture of Belonging. Ann Surg.2022 Dec 28. doi: 10.1097/SLA.0000000000005773. Epub ahead of print. PMID:36575980.
12. **Stewart JH,** Addressing the Continued Existence of Racial Inequities in Cancer Care. ASCO Post. 2023 Jan 28.

# Patents and Investigational New Drug Numbers

1. Patent application number US2008/003332

Composition and Methods for Treating Cancer. This patent relates to compositions and methods for treating cancer. Specifically relates to compositions and methods comprising nanostructures.

1. IND Number 75,685

Oxaliplatin for the treatment of peritoneal surface dissemination of colorectal and appendiceal cancers.

1. IND Number 1642

Herpes Simplex Type-1 Virus Encoded with Human Granulocyte-Macrophage Colony Stimulating Factor (RHSV-1 HGM-CSF); Oncolytic Vaccine (Imlygic) {Talimogene Laherparepvec}(TVEC)

# Chapters in books:

* 1. **Stewart JH**, Shen P, Levine EA. Patient Selection for Intraperitoneal Hyperthermic Chemoperfusion. In Ceelen W, ed. "Multidisciplinary Management of Peritoneal Carcinomatosis". New York: Springer, 2007, Chapter 13:215-225.
  2. **Stewart JH**, Levine EA. Oncology. Oncology. In O'Leary P, ed. "Physiologic Basis of Surgery". 4th edition. Baltimore: Lippencott, Williams & Wilkins, 2007, Chapter 8:188-217.
  3. Levi-Polyachenko NH, Carroll DL, **Stewart JH**. Applications of Carbon-Based Nanomaterials for Drug Delivery in Oncology. In Cataldo F, Milani P, ed. "Medicinal Chemistry and Pharmacological Potential of Fullerenes and Carbon Nanotubes". New York: Springer, 2009, Chapter 10:223-266.
  4. Randle RW, Votanopoulos KI, Levine EA, Shen P, **Stewart JH**. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Dissemination of Colorectal Cancer. In Mulholland MW, Hawn MT, Hughes SJ, Albo D, Sabel MS, Dalman RL, ed "Operative Techniques in Surgery". Philadelphia: Wolters Kluwer, 2015, Volume 2, Part 4: Chapter 48:1349-

1356.

* 1. Randle RW, Votanopoulos KI, Levine EA, Shen P, **Stewart JH**. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. In Chu QD, Gibbs JF, Zibari GB, ed “Surgical Oncology: A Practical and Comprehensive Approach”. New York: Springer, 2015, Chapter 21: 491- 512.
  2. Bryan ML, Ahmed S, Votanopoulos KI, Shen P, Levine EA, **Stewart JH**. Peritoneal Carcinomatosis. In Morgan KA, ed “Current Controversies in Cancer Care for the Surgeon”. New York: Springer, 2016, Chapter 11:185-205.
  3. **Stewart JH** and Gillory L. The Promise of Oncolytic Viral Therapy for the Treatment of Peritoneal Surface Malignancies. In Ceelen WP and Levine EA, ed “Intraperitoneal Cancer Therapy: Principles and Practice”. Boca Raton: CRC Press, 2016, Chapter 34:381-387.
  4. **Stewart JH.** Commentary on Gastric Cancer. In Fisher J, ed “Fischer’s Mastery of Surgery”. Philadelphia: Wolters Kluwer, 2018, Chapter 89*:*1140-1141.
  5. **Stewart JH.** Commentary on Echinococcal Cysts. In Fisher J, ed “Fischer’s Mastery of Surgery”. Philadelphia: Wolters Kluwer, 2018, Chapter 106*:*1314-1141.
  6. **Stewart JH.** Commentary on High Malignant Biliary Tract Obstruction. In Fisher J, ed “Fischer’s Mastery of Surgery”. Philadelphia: Wolters Kluwer, 2018, Chapter 114*:*1410-1412.
  7. **Stewart JH.** Commentary on Open and Minimally Invasive Sphincter-Preserving Radical Resection for Malignant Disease of the Middle and Lower Thirds of the Rectum. In Fisher J, ed “Fischer’s Mastery of Surgery”. Philadelphia: Wolters Kluwer, 2018, Chapter 155*:*1139-1140.
  8. **Stewart JH.** Commentary on Radical Nephrectomy for Renal Cell Cancer. In Fisher J, ed “Fischer’s Mastery of Surgery”. Philadelphia: Wolters Kluwer, 2018, Chapter 174*:*2032-2033.
  9. **Stewart JH.** Commentary on Laparoscopic Pelvic and Retroperitoneal Lymph Node Dissection. In Fisher J, ed “Fischer’s Mastery of Surgery”. Philadelphia: Wolters Kluwer, 2018, Chapter 176*:*2067- 2068.
  10. Baldwin XL, Maduuekwe UN, **Stewart JH**. Surgical Management of Postgastrectomy Syndrome. In Hawn MT, Pryor AD, Hughes SJ, Albo D, Sabel MS, Brown KR, Goldberg AJ, ed "Operative Techniques in Surgery". Philadelphia: Wolters Kluwer, 2023, Volume 1, Part 2: Chapter 22:362-

364.

* 1. **Stewart JH.** Commentary on Workup of Suspicious Cutaneous Lesions to Melanoma and Soft Tissue Tumors. In Ellison EC and Upchurch, ed “Fischer’s Mastery of Surgery”. Philadelphia: Wolters Kluwer, 2024, Chapter 67*:*604.
  2. **Stewart JH.** Commentary on Malignant. In Ellison EC and Upchurch, ed “Fischer’s Mastery of Surgery”. Philadelphia: Wolters Kluwer, 2024, Chapter 68*:*617.
  3. **Stewart JH.** Commentary on Merkel Cell Cancer. In Ellison EC and Upchurch, ed “Fischer’s Mastery of Surgery”. Philadelphia: Wolters Kluwer, 2024, Chapter 69*:*620.
  4. **Stewart JH.** Commentary on Cutaneous Squamous Cell Carcinoma. In Ellison EC and Upchurch, ed “Fischer’s Mastery of Surgery”. Philadelphia: Wolters Kluwer, 2024, Chapter 70*:*628.
  5. **Stewart JH.** Commentary on Basal Cell Carcinoma. In Ellison EC and Upchurch, ed “Fischer’s Mastery of Surgery”. Philadelphia: Wolters Kluwer, 2024, Chapter 71*:*635.
  6. **Stewart JH.** Commentary on Extremity Sarcomas. In Ellison EC and Upchurch, ed “Fischer’s Mastery of Surgery”. Philadelphia: Wolters Kluwer, 2024, Chapter 72*:*645.
  7. **Stewart JH.** Commentary on Retroperitoneal Sarcoma. In Ellison EC and Upchurch, ed “Fischer’s Mastery of Surgery”. Philadelphia: Wolters Kluwer, 2024, Chapter 71*:*656.
  8. **Stewart JH.** Commentary on Plastic and Reconstructive Surgery for Melanoma and Soft Tissue Tumors. In Ellison EC and Upchurch, ed “Fischer’s Mastery of Surgery”. Philadelphia: Wolters Kluwer, 2024, Chapter 74*:*671.
  9. **Stewart JH.** Commentary on Management of the Inguinal Lymph Node Basin for Melanoma. In Ellison EC and Upchurch, ed “Fischer’s Mastery of Surgery”. Philadelphia: Wolters Kluwer, 2024, Chapter 75*:*677.
  10. Campbell JL, **Stewart JH.** Addressing the Social Determinants of Health to Enhance Clinical Trial Participation. In Obeng-Gyasi S and Pawlik TM, ed “Social Determinants of Health in Surgery”. St. Louis:Elsevier, 2024, Chapter 7:57-63.

# Non-refereed publications:

* 1. **Stewart JH**, Mondi MA. *The Wake Forest University School of Medicine General Surgery Residency Program Two Year Reading Program*, 2006.
  2. **Stewart JH**, Hildreth AN. *The Wake Forest University School of Medicine General Surgery Residency Program Two Year Reading Program*, 2012.

# Major invited lectures

1. Meharry Medical College School of Medicine, March 2003 Matthew Walker Forum

Nashville, TN

"Locoregional Treatment of Malignant Pleural Mesothelioma with Soluble Fas Ligand"

1. Wake Forest University School of Medicine, March 2004 Department of Surgery Grand Rounds

Winston-Salem, NC

"Regional Perfusion for Cancer: Current Therapy and Future Challenges"

1. Wake Forest University School of Medicine, November 2004 Department of Surgery Grand Rounds

Winston-Salem, NC

"Breast Cancer: Current Management Strategies and Rationale"

1. High Point Regional Medical Center, April 2005 High Point, NC

"An Update on the Surgical Management of Breast Cancer"

1. Wake Forest University School of Medicine, November 2005 Department of Surgery Grand Rounds

Winston-Salem, NC

"Principals of the Surgical Management of Breast Cancer"

1. Robert Wood Johnson Medical School, November 2005 University of Medicine and Dentistry of New Jersey Department of Surgery Grand Rounds

New Brunswick, NJ

"Intraperitoneal Hyperthermic Chemoperfusion for Peritoneal Surface Malignancies"

1. Rowan Regional Medical Center, December 2005 Salisbury, NC

"Breast Cancer: Current Management Strategies and Rationale"

1. Caldwell Memorial Hospital, May 2006 Lenoir, NC

"An Update on the Surgical Management of Breast Cancer"

1. National Medical Association- Surgical Section, August 2006 Atlanta, GA

"Detection and Management of Colorectal Cancer"

1. Wake Forest University School of Medicine, September 2006 First Annual Multidisciplinary Breast Cancer Symposium Winston-Salem, NC

"New Paradigms in the Treatment of Breast Cancer"

1. North Carolina Surgical Association - Fall Meeting, September 2006 Sea Island, GA

"The Surgeon's Role in the Management of Metastatic Malignant Melanoma"

1. Wake Forest University School of Medicine, February 13, 2007 Graduate Student Association Spring Lecture

Winston-Salem, NC

"Managing Career Transitions in Professional Education"

1. Caldwell Memorial Hospital, May 2007 Lenoir, North Carolina

"New Paradigms in the Treatment of Breast Cancer"

1. Twin Cities Regional Medical Center, June 2007 Winston-Salem, NC

"New Paradigms in the Treatment of Breast Cancer"

1. Wake Forest University School of Medicine, June 2007

Department of Dermatology, Spring Lecture Series, Distinguished Lecturer Winston-Salem, NC

"Malignant Melanoma: Current Management Strategies and Rationale"

1. Congressional Black Caucus, Health Issues Forum, September 28, 2007 Congressional Black Caucus Leadership Weekend

Washington, DC

"Toward a Value-Based Healthcare System: Where Do We Go From Here?"

1. Temple University, Department of Surgery Grand Rounds, November 14, 2007 Philadelphia, PA

"Intraperitoneal Hyperthermic Chemoperfusion: A Novel Treatment Paradigm for Peritoneal Surface Malignancies"

1. North Carolina Chapter of the American College of Surgeons Meeting, December 6, 2007 New Hanover Regional Medical Center

New Hanover, NC

“Novel Approaches to the Management of Peritoneal Surface Malignancies”

1. Twin Cities Medical Society, January 29, 2008

"The Management of Peritoneal Surface Dissemination of Colorectal Cancer Using Intraperitoneal Hyperthermic Chemoperfusion"

Winston-Salem, NC

1. Southeastern Symposium on Breast Cancer Disparities, March 28, 2008 Winston-Salem, NC

"Disparities in Breast Cancer Incidence"

"Breast Cancer: Current Management Strategies and Rationale"

1. Hyperthermia and Nanomaterials: Nanotechnology Approaches Medicine, April 7, 2008 Winston-Salem, NC

"Multiwalled Carbon Nanotubes and Hyperthermia for the Treatment of Colorectal Cancer"

1. Wake Forest University School of Medicine, May 2008 Department of Plastic Surgery Grand Rounds

Winston-Salem, NC

"Breast Cancer: Current Management Strategies and Rationale"

1. Wake Forest University Best Health, September 4, 2008 Winston-Salem, NC

"Breast Cancer Vaccine: A Clinical Trial"

1. The Halsted Society Annual Meeting, September 12, 2008 Cashiers, NC

"Novel Approaches to the Management of Peritoneal Surface Dissemination of Colorectal Cancer"

1. Winston-Salem Chamber of Commerce Tech Council, September 24, 2008 Winston-Salem, NC

"The Clinical Potential of Carbon Nanotubes for the Treatment of Colorectal Cancer"

1. The North Carolina Triad Affiliate of the Susan G. Komen for the Cure 10th Anniversary Celebration Luncheon, March 25, 2009

Winston-Salem, NC

"Breast Cancer Research in North Carolina: Hope for the Future”

1. Pink Ribbon Talks, Cancer Services, October 2009 Winston-Salem, NC

"Breast Cancer: A Surgical Oncologist’s Perspective"

1. Wake Forest University School of Medicine, January 2010 Department of Radiology Grand Rounds

Winston-Salem, NC

"Tumor Immunotherapy at Wake Forest Health Sciences"

1. Wake Forest University School of Medicine, April 2010 Women’s Health Center of Excellence

Winston-Salem, NC

"Pathways to Promotions Panel: Assistant to Associate Professor"

1. National Cancer Institute Center to Reduce Health Disparities Professional Development Workshop, April 2010

Rockville, MD

"Work/Home Balance: Keeping it all in Perspective"

1. Howard University College of Medicine, May 2011 Washington, DC

"A Surgeon’s Journey To Translational Research"

1. Wake Forest School of Medicine, April 2012 Department of Hematology and Oncology Grand Rounds Winston-Salem, NC

"Immunotherapy for Cancer, Current Approaches and Rationale"

1. VSVirus Workshop, September 2012 Big Sky, MT

"Realizing the clinical potential of VSV as a vaccine platform and anticancer drug**"**

1. The Halsted Society Annual Meeting, September 2012 San Diego, CA

"Asa Yancey: A Quiet Giant in American Surgery"

1. The Wake Forest Department of Dermatology, April 2013 Guest Spring Lecturer

"Melanoma: Current Challenges, Future Challenges"

1. Wake Forest School of Medicine, March 2014 Department of Surgery Grand Rounds Winston-Salem, NC

"Health Care Reform: Red, Blue and You"

1. Advances in Cancer Immunotherapy-North Carolina, October 2014 Charlotte, NC

"The Fundamentals of Antigen Presentation"

1. Georgia Reagents University/ Medical College of Georgia, January 2015 Augusta, GA

"Vesicular Stomatitis Virus: An Attractive Oncoimmunotherapy Against Colon Cancer"

1. The American Association for Cancer Research Annual Meeting, April 2015 Philadelphia, PA

"Work-Life Blend: Keeping it All Together"

1. Howard University College of Medicine, May 2015 Washington, DC

Principle Speaker for Medical Student Hooding Ceremony "Today is Your Day, But Tomorrow is a New Day"

1. National Medical Association Annual Meeting, August 2015 Detroit, MI

Sinkler Lecturer

"The Surgeon’s Role in Value-Based Health Care: Is There a Change on the Horizon?"

1. Duke University School of Medicine, September 2015 Durham, NC

Grand Rounds Speaker

“The Value Proposition in Surgery: Times are Changing.”

1. Boston University School of Medicine, December 2016 Boston, MA

Surgery Conference

“Value in Academic Surgery: Where Will We Stand in the Future?”

1. The University of Illinois, Chicago School of Medicine, August 2017 Chicago, IL

Cancer Center Grand Rounds

“Value-Based Oncology Care in Academic Medical Centers: The Future is Now”

1. Morehouse School of Medicine, August 2017 Atlanta, GA

Strategic Leadership Group Meeting “Capitalizing on Value as a Strategy for Success”

1. The American College of Surgeons Clinical Congress, October 2017 San Diego, CA

Session on Melanoma Management

“Melanoma of the Back: Treatment Paradigms in 2017”

1. Clinical Research as a Care Option, April 2018 Boston, MA

“Healthcare and Clinical Research Ecosystems”

1. Clinical Research as a Care Option, September 2018 Boston, MA

“Academic Medical Centers, the Community and Clinical Research”

1. Society of University Surgeons Mid Career Course, February 2019 Houston, TX

“Recognizing Red Flags in the Recruitment Process”

1. Clinical Research as a Care Option, April 2019 Raleigh, NC

“At the Starting Stages: Creating Infrastructure to Provide Outstanding Clinical Research”

1. Louisiana State University Oncology Grand Rounds, August 2019 Shreveport, LA

“The 21st Century Cancer Center: A Vehicle to Improve Regional and National Health”

1. American College of Surgeons Clinical Congress, October 2019 San Francisico, CA

Panelist, “The Role of Surgeons in Immunotherapy” “Oncolytic Viral Therapy for Non-Melanoma Malignancies”

1. Temple University Department of Surgery, February 2020 Philadelphia, PA

Dr. Robert D. Harwick Distinguished Lecturer

“Novel Immunotherapy Approaches to Peritoneal Surface Malignancies”

1. Annual Leadership Conference, Congressional Black Caucus, September 2020 Virtual Presentation Due to COVID19

Moderator, “Medical Distrust in the Era of COVID19”

1. American Board of Surgery, Quarterly Retreat, September 2020 Virtual Presentation Due to COVID19

Retreat Leader, “Institutional Racism in American Surgery”

1. American College of Surgeons Clinical Congress, October 2020 Virtual Presentation Due to COVID19

Moderator, “Alternative Payment Models in Surgery: What is our Future?”

1. National Minority Quality Forum Annual Meeting, October 2020 Virtual Presentation Due to COVID19

“The Current Status of Health Inequities in Cancer”

1. Morehouse College of Medicine, January 2021 Virtual Grand Rounds Due to COVID 19

“The Surgeon’s Role in Value Based Oncology Care”

1. Atirum Health Department of Surgery, June 2021 Virtual Grand Rounds Due to COVID 19

“The Surgeon’s Role in Value Based Oncology Care”

1. Southeastern Surgical Congress, August 2021 Virtual Presentation Due to COVID 19 “Telemedicine in Surgery: Emerging Opportunities”
2. The University of South Alabama Department of Surgery, October 2021 Visiting Professor

“A Historical Perspective on the Development of Oncolytic Viral Therapy”

1. The Johns Hopkins School of Medicine, October 2021 Virtual Grand Rounds Speaker Due to COVID19

“Creating Value-Based Oncology Ecosystems in Academic Medical Centers: Lessons Learned and Emerging Opportunities”

1. The Washington University School of Public Health, March 2022 Virtual Grand Rounds Speaker Due to COVID19

“Value-Based Oncology as a Driver for Improved Public Health”

1. Cornell-Brooklyn Surgery Grand Rounds, March 2022 Virtual Grand Rounds Speaker Due to COVID19

“Creating A Value-Based Oncology Ecosystem to Meet the Needs of The Patients of Brooklyn”

1. The University of Utah School of Medicine, May 2022 Virtual Grand Rounds Speaker Due to COVID19

“Creating Value-Based Oncology Ecosystems in Academic Medical Centers: Lessons Learned and Emerging Opportunities”

1. Boston University Surgery Grand Rounds, June 2022

Virtual Grand Rounds

“Understanding Oncology Ecosystems to Address Cancer Equity”

1. Louisiana Biomedical Research Network, January 2023

Baton Rouge, LA

Annual Meeting Lecturer

“Oncolytic Viral Therapy: Perfecting Nature’s Nanotubes”

1. ECOG-ACRIN Spring Meeting, May 2023

Chicago, IL

Plenary Session

“Addressing Barriers to Clinical Trial Participation”

1. The Society for Surgery of the Alimentary Tract GI Summit, January 2024

New Orleans, LA

Plenary Session Speaker

“The Role of the Surgeon in Addressing Cancer Inequities”

# Current Funding:

**a. Clinical Trials Leadership**

Amgen Biosciences

“A Phase I Trial of Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies” 06/01/19-present $570,000

Role: Study Chair 5% Effort

# Past Funding:

* 1. **Research Funding**

University of Illinois Presidential Scholar Award

“Developing Immunotherapeutic Approaches to Peritoneal Surface Malignancies” 05/15/18- 6/30/2022 $1,500,000

Role: PI 30% Effort

Susan B. Komen, Chicago Affiliate “Chicago Health Equity Initiative (CHEI) 11/01/2020 $475,000

Role: PI 10% Effort

National Cancer Institute

Clinical Investigator Team Leadership Award Supplement to Wake Forest CCSG 5P30CA012197 (CCSG)

09/01/13-8/30/15 $50,000

Role: Program Director 10% Effort

National Cancer Institute

Oncolytic Vesicular Stomatitis Virus for The Treatment of Colorectal Cancer

5KO8 CA131482 07/01/08-12/30/14 $567,000

PI: John Stewart Role: PI 75% Effort

Robert Woods Johnson Foundation

Novel Treatment Paradigms for the Treatment of Peritoneal Surface Malignancies

07/01/08-06/30/12 $416,557

PI: John Stewart Role: PI 75% Effort

National Cancer Institute

Navigation to Improve Participation of Underserved Populations in NCI- Sponsored Surgical Trials Supplement to Wake Forest CCSG

5P30CA012197 (CCSG) 09/01/09-08/30/11 $125,000

PD: John Stewart Role: PD 10% Effort

Avon Foundation

Survivors in Service (SIS) Navigation and Outreach Program 07/01/06-06/30/10 $500,000

PI: Wake Forest SOM Role: Program Director

National Cancer Institute

African American Men Prostate & Colorectal Cancer Belief Project

1R21CA113943 05/01/06-04/30/08 $200,000

PI: Thomas Acury Role: Co-investigator 5% Effort

National Cancer Institute

Outcomes of Omission of Radiation with Lumpectomy (BCS) Among Low-Income Women 1R01CA121317 04/01/06-03/31/08 $500,000

PI: Roger Anderson Role: Co-investigator 5% Effort

National Institute of Allergy and Infectious Diseases

Research Supplement to Promote Diversity in Health Related Research

3R01AI0329830 8/15/06-07/01/08 $150,000

PI: Doug Lyles Role: Mentee 30% Effort

Centers for Disease Control

Breast and Prostate Cancer Data Quality and Patterns of Care Study

5U01DP000264 09/30/05-08/31/08 $330,908

PI: Roger Anderson Role: Co-investigator 5% Effort

# Training and Mentoring Grants

National Cancer Institute

The Chicago Collaborative to Promote and Advance Cancer Health Equity 5U54CA202997

09/01/20-08/31/25 $901,036

PI: John Stewart. Role: MPI 15% Effort

National Cancer Institute

Translational Research in Surgical Oncology

2T32CA093245-11A1 09/15/16-08/31/18 $887,685

PI: Kim Lyerly Role: Co-PI, Clinical Trials Track Leader 10% Effort

National Institute of General Medical Sciences

Training Physician Scientists at the Interface of Trauma and Regenerative Medicine 4T32GM099606-04 7/01/13-08/09/15 $1,670,650

PI: John Stewart Role: Founding PI/PD 5% Effort

The Gertrude B. Elion Foundation Research Foundation

Patterns of Care for Women with Ductal Carcinoma In Situ in North Carolina 07/01/06-06/31/07 $35,000

PI: LeRon Jackson Role: Primary Mentor 5% Effort

# Clinical Trials Leadership

Orin Smith Family Foundation

“A Multi-Center Randomized Trial to Evaluate Hematologic Toxicities after Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin or Mitomycin in Patients with Appendiceal Tumors” 7/01/09-12/30/15 $125,000

Role: Co-PI 10% Effort

Cancer Insight

“A Prospective, Randomized, Blinded, Placebo-Controlled, Phase Iib Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs. Unloaded YCWP

+ DC in Stage III and Stage IV (resected) Melanoma to Prevent Recurrence” 09/01/14-08/09/15 $11,500

Role: Local PI 5% Effort

NewLink Genetics

“A Phase IIB Study of Ipilimumab with or without HyperAcute-Melanoma Immunotherapy for Stage IV Melanoma Patients”

05/09/14-08/09/15 $33,000

Role: Local PI 5% Effort

Argos Therapeutics

“A Phase 3 Randomized Study of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment for Advanced Renal Cell Cancer”

5/01/13-08/09/15 $146,600

Role: Local PI 10% Effort

Eastern Cooperative Oncology Group

“Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery”

3/15/13-08/09/15 $14,125

Role: Local PI 5% Effort

Bristol-Myers Squibb

“A Multi-Site Retrospective Observational Study of US Patients with Unresectable or Metastatic Melanoma Receiving Ipilimumab (Yervoy) as First-Line Therapy”

03/01/13-08/09/15 $45,000

Role: Local PI 5% Effort

GlaxoSmithKline

“A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection” (COMBI-AD)

01/10/13-08/09/15 $92,000

Role: Local PI 10% Effort

Henry Jackson Foundation for the Advancement of Military Medicine

“Prospective, Randomized, Single-Blind, Multi-center Phase 2 Trial of the HER2/neu Peptide GP2+GM-CSF vaccine vs. Gm-CSF alone in HLA-A2+ or the Modified HER2/neu Peptide AE37+GM- CSF Vaccine vs GM-CSF Alone in HLA-A2+ Node+ and High-risk Node Negative Breast Cancer Patients to Prevent Recurrence.”

03/01/08-08/09/15 $54,348

Role: Local PI 5% Effort

Prometheus Therapeutics

“Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy”

10/4/11-08/09/15 $28,100

Role: Local PI 5% Effort

Sanofi Aventis

“A Phase I Trial of the Treatment of Peritoneal Dissemination of Gastrointestinal Malignancies via Intraperitoneal Hyperthermic Chemoperfusion with Oxaliplatin”

03/15/07-11/19/07 $50,000

Role: PI for IIT 20% Effort

# Consultant appointments:

Textbook Editor Activities

* Invited Editor, *Fischer’s Mastery of Surgery,* 7th Edition, 2017
* Editor, *Current Problems in Surgery,”* Current Approaches to Peritoneal Surface Malignancies”, 2021
* Associate Editor, *Mastery of Surgery,* 8th Edition, 2024 Journal Peer Review Activities
* Editorial Board, *The American Surgeon*
* Reviewer, *Cancer*
* Reviewer, *Journal of Urology*
* Reviewer, *Journal of Surgical Research*
* Reviewer, *Journal of Pediatric Surgery*
* Reviewer, *Annals of Surgical Oncology*
* Reviewer, *JAMA Oncology*
* Reviewer, *Surgery*
* Reviewer, *International Journal of Hyperthermia*
* Reviewer, M*olecular Therapy- Nucleic Acids*
* Reviewer, *Journal of Biomedical Engineering*
* Reviewer, *JAMA Surgery*

National Institutes of Health Study Sections and Advisory Committees

5/18/06-National Cancer Institute ZCA1 SRRB-4 (I1)

Orientation - Applications for Emerging Technologies for Cancer Research

6/20/06-National Cancer Institute ZCA1 SRRB-4 (O1)

Applications of Emerging Technologies for Cancer Research

3/7/07-National Cancer Institute ZCA1 SRRB-4 (W1)

Workgroup Application of Emerging Technologies Orientation

4/3/07-National Cancer Institute ZCA1 SRRB-4 (M1)

Application of Emerging Technologies for Cancer Research

2/14/08-National Cancer Institute ZCA1 SRRB-4 (T2)

Workgroup - Application of Emerging Technologies for Cancer Research

3/19/08-National Cancer Institute ZCA1 SRRB-4 (M1)

Application of Emerging Technologies for Cancer Research

6/26/08-National Cancer Institute ZCA1 SRRB-4 (O1)

Application of Emerging Technologies for Cancer Research

9/17/08- National Cancer Institute ZCA1 SRRB-4 (T1)

Workgroup - Application of Emerging Technologies & Sample Prep for Cancer Research

10/23/08-National Cancer Institute ZCA1 SRRB-4 (J1)

Application of Emerging Technologies & Sample Prep for Cancer Research

2/5/09-National Cancer Institute ZCA1 SRLB-V (I1)

Workgroup – IMAT

3/19/09-National Cancer Institute ZCA1 SRLB-V (M1)

Application of Emerging Technologies for Cancer Research

5/20/10-National Cancer Institute ZCA1 SRLB-4 (T1)

Workgroup - Transdisciplinary Research in Energetics and Cancer

6/28/10-National Cancer Institute ZCA1 SRLB-R (O1)

Emerging Technologies for Cancer Research

7/6/10-National Cancer Institute ZCA1 SRLB-4 (O1)

Transdisciplinary Research in Energetics and Cancer

5/21/12-National Cancer Institute BTSS

Bioengineering, Technology and Surgical Sciences Study Section

6/13/13-National Cancer Institute CII

Cancer Immunopathology and Immunotherapy Study Section

3/14/14-National Cancer Institute ZGM1 PPBC-C (CT)

Clinical Trial Planning Grant

5/29/14-National Institute of General Medical Sciences ZGM1 TWD-5 (PD)

Site Visit to University of Washington

6/18/14-National Institute of General Medical Sciences ZGM1 TWD-5 (PD)

Site Visit to Massachusetts General Hospital

7/11/14-National Institute of General Medical Sciences ZGM1 TWD-5 (PD)

Institutional Postdoctoral T32 Review

5/4/15-National Institute of General Medical Sciences ZGM1 TWD-5 (PD)

Site Visit Boston University

5/29/15-National Institute of General Medical Sciences ZGM1 TWD-5 (PD)

Site Visit University of Colorado

7/10/15-National Institute of General Medical Sciences ZGM1 TWD-5 (PD)

NIGMS Postdoctoral T32 Review

11/2015- National Cancer Institute Cancer Therapy Evaluation Program TVEC Development Team

5/2019-National Institute of General Medical Sciences ZGM1 TWD-5 (PD)

Site Visit Brown University

6/2019-National Institute of General Medical Sciences ZGM1 TWD-5 (PD)

Site Visit Loyola University

7/09/19-National Institute of General Medical Sciences ZGM1 TWD-5 (PD)

NIGMS Postdoctoral T32 Review

7/14/20-National Institute of General Medical Sciences ZGM1 TWD-5 (PD)

NIGMS Postdoctoral T32 Review

Veterans Administration Study Sections 2/25/15-Veterans Administration HBCU

VA-ORD Historically Black College and University Research Scientist Training Program

# Professional awards and special recognitions:

|  |  |
| --- | --- |
| 1987-1991 | Herbert Lehman Education Foundation Scholarship |
| 1987-1991 | Louisiana Board of Trustees Scholarship |
| 1987-1991 | T.H. Harris Academic Scholarship |
| 1990 | Alpha Epsilon Delta Honor Society |
| 1990 | Mortar Board Honor Society |
| 1990 | Omicron Delta Kappa Honor Society |
| 1991 | The USA Today All-Academic Team |
| 1991-1995 | Howard University College of Medicine Alumni Association Scholarship |
| 1992 &1993 | NIH Summer Intramural Research Training Award |
| 1993 | Office of Medical Education- Medical Physiology Tutor |
| 1994 | Student National Medical Association President’s Award- National Legislative Affairs |
|  | Chairperson |
| 1995 | Dr. Jack E. White Award for Excellence in Cancer Research |
| 1995 | Granady Award for Excellence in Internal Medicine |
| 1995 | Department of Surgery Pen Award |
| 1995 | Leroy Weekes, M.D. Award in Obstetrics and Gynecology |
| 1995 | Office of Student Affairs Service Award |
| 1995 | Ralph C. Kennedy, M.D. Award in Clinical Psychiatry |
| 1995 | First Prize- SNMA Scientific Forum |

|  |  |
| --- | --- |
| 2002 | AACR Scholar-in-Training Award |
| 2004 | NSABP Minority Investigator Travel Award |
| 2006-2015 | CRCA Top Surgeon |
| 2007 | Society of Black Academic Surgeons Leadership Institute |
| 2008 | Robert Wood Johnson Foundation- Harold Amos Fellow |
| 2009, 10, 11 | Student National Medical Association Faculty Award |
| 2010 | Alpha Omega Alpha |
| 2011-2015 | US News and World Report Top Doctors Award |
| 2012-2014 | Wells Fargo Scholar, Babcock School of Management |
| 2012-2015 | Best Doctors in America |
| 2013-2015 | NCI Cancer Clinical Investigator Team Leadership Award |
| 2015 | Hooding Ceremony Speaker, Howard University College of Medicine |
| 2018-2022 | Presidential Scholar, University of Illinois |
| 2023 | Howard University College of Medicine Distinguished Alumni Award |

**Organizations and participation: (Offices held, committee assignments, etc.)**

Alpha Omega Alpha

2010-Present: Member

American Association for Cancer Research (AACR)

1998-Present: Member

2014-2017: Minorities in Cancer Research Committee

2017-Present: Finance and Audit Committee

2019-2020: AACR Annual Report Writing Committee

2018-2021: Jane Wright Award Review Committee

2022-Present: Cancer Center Director Steering Committee

American Board of Medical Specialties

2021-Present: Health Policy Committee

American Board of Surgery

2013-Present: Member

2013, 2016: Associate Examiner

2016-2018: Advanced Surgical Oncology Consultant

2018-2019: Director

2019-2021: Councilor

2021-Present: Director

2023-Present: Chair, Finance Committee

2023-Present: Audit Committee

American College of Surgeons

2007-Present: Fellow

2013-2023: General Surgery Advisory Council

2017-2019: Vice Chair, General Surgery Advisory Council

2019-2023: Chair, General Surgery Advisory Council

2019-2023: Board of Regents Member Services Liaison Committee

2019-2023: Chair, Council of Advisory Council Chairs

2020-2022: COVID19 Communications Committee

2022-Present: ACS Foundation Board of Directors

2023-Present: Patient Education Committee

American College of Surgeons Oncology Group

2004-2013: Investigator

2007-2010: Chairman, Colorectal Cancer Surgery Taskforce

2004-2013: National Adjuvant Breast and Bowel Project - Investigator

American Medical Association

2004-Present: Member

American Society for Clinical Oncology (ASCO)

1998-Present: Member

2016: Faculty, ASCO University- Surgical Oncology Primer

2017-Present: Committee on Health Equity

2019: Consensus Ratings Group- Late-Stage Colorectal Cancer

American Surgical Association

2022-Present: Member

2023-Present: Audit Committee

Association for Academic Surgery

2006-Present: Member

2011-2013: Publications Committee

Cytokine Working Group

2010-2015: Investigator

Halsted Surgical Society

2012-Present: Member

2014: Chair, Local Program Committee

2015-2017: Program Committee

2017: Chair

2020-2023: Board of Directors

2023: Chair

National Medical Association

2004-Present: Member

Society of Black Academic Surgeons

2005-Present: Member

2009-2012: Program Committee

2014-2022: Finance Committee

2015-2016: Treasurer-Elect

2016-2019: Treasurer

2023-Present: President-Elect

Society of Surgical Oncology

2007-Present: Member

2009-2013: Member, Disparities Committee

2013-2016: CME Committee

2014-2019: Editorial Board, Annals of Surgical Oncology

Society of University Surgeons

2010-Present: Member

Southeastern Surgical Congress

2005-Present: Member

2009-2011: Gold Medal Award Committee

2012: Chair, Gold Medal Award Committee

2013-2015: Councilor, North Carolina

2014-2020: Representative to the ACS General Surgery Advisory Council

2017-2023: Continuing Medical Education Committee

2022-2023: Chair, Program Committee

Southern Surgical Association

2014-Present: Member

2021-Present: Faculty for the Leadership Development Program

2023-Present: Shipley Award Committee

# Teaching responsibilities including continuing education:

Postdoctoral Fellows

Vijay Kumar 2022-present

“Tumor Microenvironment Changes after Treatment with Oncolytic Viruses”

Maria Jose Calderon 2018- 2021

“Immunologic Mechanisms of Response to Intraperitoneal Oncolytic Viral Therapy”

Surgery Residents Aaron Blackham

Research Mentor, 2010-2012

“VSV as a Treatment for Disseminated Cancer”

Reese Randle

Research Mentor, 2012-2013

“VSV as a Treatment for Neuroendocrine Tumors”

Michelle Bryan

Research Mentor, 2013-2015

“Oncoimmunotherapeutic Effects of VSV in Peritoneal Surface Dissemination of Colorectal Cancer”

Cecilia Ong

Research Mentor, 2016-2018

“Socioeconomic Determinants of Participation in Surgical Oncology Clinical Trials”

Graduate Students

Nicole Levy-Polyachenco, Ph.D., WFU Biomedical Engineering Program 2007 Research Mentor, 2005-2007

Thesis Co-Advisor

“Carbon Nanomaterials for Oncology Treatment Options”

Elizabeth Graham-Gurysh, PhD., WFU Biomedical Engineering Program 2016 Research Mentor, 2013-2015

Thesis Co-advisor

“CXCR4 Targeted Polymer Nanoparticles for Enhanced Photothermal Ablation of the Brain Metastasis of Breast Cancer”

Eleanor, McCabe, WFU Biomedical Engineering Program 2018 Thesis Committee

“Hybrid Donor-Acceptor Polymer Particles for the Treatment of Metastatic Colon Cancer”

Medical Students

LeRon C. Jackson, WFUSOM, 2007

Primary Mentor for the Gertrude B. Elion Mentored Scholarship, 2006

“The Management of DCIS in Underserved Women in North Carolina”

Jeremy Webb, WFUSOM, 2010

Summer Research Program Mentor - 2007

“Sensitivity of Colorectal Cancer Cells to Oxaliplatin after Hyperthermia”

Shannon Rosati, WFUSOM, 2008 Research Mentor, 2007-2008

“Interferon Responses in Colorectal Cancer Cells after Infection with VSV”

Brandon Johnson, WFUSOM, 2011 Summer Research Mentor – 2008

“Animal Models for the Treatment of Colorectal Cancer Cells with VSV”

Melanie Robinson, WFUSOM, 2013 Summer Research Mentor - 2009

“An Evaluation of Attitudes toward Genetic Testing in Minority Patients with Breast Cancer”

E. Nicole Parson, WFUSOM, 2012 Research Mentor – 2009-2010

“Outcomes after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Surface Dissemination from Ovarian Neoplasms”

Miiko Richards-Rowley, WFUSOM, 2014 Summer Research Mentor - 2009

“A Business Model for Understanding the Impact of Breast Cancer Navigation Programs for Underserved Women”

Darian LaNeave, WFUSOM, 2017 Summer Research Mentor - 2014

“Molecular Determinants of Susceptibility of Colorectal Cancer Cells with VSV”

Gwyenth Davis, WFUSOM, 2018 Summer Research Mentor - 2015

“Immunologic Consequences of Intraperitoneal VSV Injections for the Treatment of CRC”